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GENETIC, BIOCHEMICAL, AND FUNCTIONAL CHARACTERIZATION OF HEME
METABOLISM IN GROUP A STREPTOCOCCUS

by

ANKITA J. SACHLA

Under the Direction of Zehava Eichenbaum, PhD

ABSTRACT
Heme is vital to a variety of cellular functions in bacteria ranging from energy generation
to iron reserve. Group A streptococcus (GAS) is a prevalent bacterial pathogen that is
responsible for an array of human diseases ranging from simple, self-limiting, mucosal and skin
infections to invasive and systemic manifestations. GAS needs iron for growth and can satisfy
this nutritional requirement by scavenging the metal from heme. The pathogen produces
powerful hemolysins that facilitate heme release during infection. Heme is captured and relayed
through the GAS cell wall and cytoplasmic membrane by dedicated receptors and transporters.
To-date, the fate of the acquired heme is unknown in Streptococci. Although heme is
nutritionally beneficial for GAS growth, its pro-oxidant and lipophilic nature makes it a liability

with damaging effects on cellular components. The conundrum associated with heme use is
particularly pertinent to GAS pathophysiology since invasive GAS infections involve massive
hemolysis and the generation of unescorted heme in excess. In this dissertation, I aimed to
describe the mechanisms that GAS uses for heme catabolism while managing its toxicity. I
conducted a biochemical characterization of a new enzyme, HupZ in GAS that degrades heme in
vitro. Similar to the heme oxygenase-1 (HO-1), HupZ activity leads to the formation of iron, CO,
and a biliverdin-like product. I also investigated the impact of heme on GAS physiology and
identified key mediators in the repair and detoxification process. This study demonstrated that
heme exposure leads to a general stress response that involves the activation of antioxidant
defense pathways to restore redox balance. Further, I studied a 3-gene cluster, pefRCD
(porphyrin-regulated efflux RCD), which was activated by environmental heme, and provided
support to my hypothesis that the pefRCD gene encodes a heme-sensing regulator (PefR) and
heme efflux system (PefCD). I showed that the pef system protects GAS cells from hemeinduced damage to the membrane and DNA by preventing cellular accumulation of heme. In
conclusion, this dissertation addresses key knowledge gaps in GAS physiology and provides new
insights into heme metabolism of GAS.

INDEX WORDS: Heme tolerance, Group A streptococcus, Gram-positive, heme sensing,
mutational analysis, heme toxicity, heme tolerance, PefRCD transporter, heme efflux,
heme degradation, HupZ protein, UV-vis spectroscopy, iron and CO release.
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1
1.1

GENERAL INTRODUCTION

Group A streptococcus

Group A streptococcus (GAS) also commonly known as Streptococcus pyogenes is a Grampositive, beta-hemolytic, obligate human pathogen that can adapt and flourish in numerous micro
environments within the human body. GAS infections are realized in a range of manifestations
from superficial, self-limiting infections of the mucous membranes and skin (pharyngitis,
pyoderma, impetigo, etc.) to more severe and rare invasive infections (bacteremia, necrotizing
fasciitis, streptococcal toxic shock syndrome, etc.) (1, 2). In certain patients GAS can cause
autoimmune complications in the form of glomerulonephritis or acute rheumatic fever (3, 4).
Occurrences of rheumatic fever is linked to rheumatic heart disease and neurological
complications (5).

1.2

GAS burden.

GAS infections are ranked among the top 10 causes of infectious mortality (1). Worldwide, GAS
causes ~700 million infections every year of which 1.8 million are invasive manifestations with
25% mortality rate (~450,000 patients succumb to death) (6). The non-invasive infections are
treated with the β-lactam group of antibiotics; however, the invasive manifestations of GAS are
rapid, aggressive, and difficult to manage. Often surgical amputation is the only available
alternative that significantly impairs the lifestyle of the patients and requires extensive care (7).
Manifestations of acute-rheumatic fever following GAS pharyngeal infections cause damage to
joints and heart and account for a significant morbidity (~223,000 cases worldwide) (3, 4). In the
absence of efficacious and licensed vaccines made for human practices, the understanding of the
GAS-host interactions is an important strategy that may facilitate the design of novel therapeutics
for combating GAS infections (8).
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1.3

GAS virulence

The pathophysiology of GAS is very complex; GAS is a versatile pathogens that is armed with
more than 50 identified virulence factors, some are shared by all strains (consisting of the core
virulon) while others are strain-specific. GAS virulence factors contribute to the different stages
of infection and pathologies, occasionally serving redundant functions. The highlights of some of
GAS core virulence factors are as follows:
M protein: The M protein is the major surface and virulence determinant in GAS, it protects the
bacterium from phagocytosis and facilitates adherence to the host epithelium (2). The cell wall
anchored M protein is encoded by the emm gene. The hyper variability of M protein is the basis
for GAS serotyping. There are more than 200 M protein types identified in GAS up to date (6).
Capsule: GAS produces hyaluronic acid capsule that coats the bacterial cell and protects it from
complement deposition and phagocytosis (9-11). Capsule biosynthesis in GAS is brought about
by the hasABC operon, which codes for membrane bound synthase leading to the assembly of a
linear hyaluronic acid polymer made out of alternating units of glucuronic acid β-1,-3 linked to
N-acetylglucosamine (12, 13). The capsular gene expression is increased during GAS growth in
blood
Cytolysins: GAS cells produces two hemolysins, SLO and SLS. SLO is an oxygen-labile,
cholesterol-dependent toxin that is produced throughout the exponential phase of growth (14).
The SLO protein oligomerizes in the membrane of the host cells, creating large pores (25-30 nm)
and leading to cellular damage and activation of apoptotic pathways (15). SLS, which consists of
a peptide, is an oxygen stable toxin used by GAS to resist immune killing. This toxin can create
hydrophilic pores in the neutrophils membrane. SLS biosynthesis and export is encoded by the
sagA-I operon, which is expressed during the stationary phase of growth (16, 17).
SpeB: The Streptococcal pyrogenic exotoxin B is a cysteine protease secreted by GAS cells from
the late exponential to stationary phase (18, 19). In the activated form, the SpeB zymogen aids in
immunoglobulin degradation and the establishment of GAS in skin and soft tissue niches (20-22).
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Peptidases: The C5a peptidase called ScpA is a serine protease that cleaves C5a chemoattractant.
The ScpA protein prevents the recruitment of neutrophils to the site of infection and the
generation of the peroxide burst associated with the phagocytosis process occurring subsequent to
neutrophil infiltration (23, 24). ScpC is another cell wall anchored peptidase, which inactivates
cytokines (e.g. interleukin-8) and impairs the recruitment of neutrophils (25).
Streptodornases (deoxyribonucleases): The neutrophil extracellular traps (NET) are excessive
extracellular DNA network produced by neutrophils. The NET captures bacteria and facilitates
their killing using the antimicrobial effectors associated with it and enables bacterial detection by
the cells of the immune system. GAS produce and secret two DNases, Sda1 and Sda2, which act
to dissolve the NET and thus prevent subsequent detection (by TLR9) and clearance (26, 27).

In addition to the virulence factors described above, GAS secretes a number of proteins capable
of modifying the host molecules and tissues and help in the pathogen dissemination and/or
subversion of the host immune response. For example the streptokinase (Ska) protein is a
plasminogen activator secreted by GAS during invasive infections. Ska converts the host
plasminogen to the active protease, plasmin. Plasmin is then recruited and used by GAS to
dissolve the host extracellular matrix (ECM) and facilitates the bacterial spread (28).

Like the majority of pathogens, GAS requires iron for growth and this elemental requirement is
linked to the virulence potential of GAS (29-31). During infections heme and hemoproteins serve
as a largest reserve for metal iron. GAS is endowed with a number of molecular mechanisms to
acquire iron from the host heme (and or hemoproteins) (30, 32, 33). In this respect, heme
metabolism is central for the survival and success of GAS as a human pathogen; yet significant
knowledge gaps regarding this aspect in GAS physiology exist.
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1.4

Dissertation objectives and significance

The purpose of this dissertation is to describe the mechanisms for heme homeostasis in GAS. In
chapter 1, I laid the theoretical foundation for my studies by providing a review on the current
understanding of heme, its juxtaposing nature and interactions in bacterial systems. In chapter 2, I
addressed the fate of the intracellular heme in GAS by characterizing a new enzyme, named heme
utilization protein Z (HupZ). Dr. Mahamoudou Ouattara, a former member and colleague in Dr.
Eichenbaum’s lab, cloned and begun describing this enzyme. I devoted my efforts in 1)
optimizing the heme degradation process, 2) identifying the products of heme catabolism and 3)
conducting in-silico analysis to establish the phylogenetic placement of HupZ. The elucidation of
heme biotransformation by HupZ could serve as a novel pathway for heme catalysis in
streptococcal pathogens. Successful mammalian infections involve evasion of the host defenses,
here streptococcus is exposed to highly oxidative environment and reactive species (34). In
addition, as a hemolytic pathogen that spreads through the blood, GAS is likely to encounter toxic
levels of heme during infection. In Chapter 3, I described the impact of environmental heme on
GAS physiology. I illustrated the toxic implications of environmental heme, characterized GAS
response to heme stress, and identified GAS mechanisms for heme tolerance. In Chapter 4, I
aimed to describe the function of a new pathway, named pefRCD (porphyrin-regulated efflux
RCD) and its contribution to heme tolerance in GAS. This investigation revealed that the PefCD
protein consists of an ABC-type transporter that exports heme and defends GAS cellular
components from heme damage. Together, this dissertation provides new insights into heme
metabolism in GAS and in Streptococcus overall. Because of the importance of these new
pathways to streptococcal biology and interactions of GAS with its human hosts, they consist of
potential targets for new therapeutic modalities against streptococcal infections.
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2

CHAPTER 1. THE CORNUCOPIAS INTERACTIONS OF PORPHYRINHEME IN A BACTERIAL SYSTEM

Summary for mini-review: There is a significant portion of research dedicated to heme
acquisition, uptake, and utilization in bacteria. However, the important part that heme
plays in the production of redox stress and cellular damage in bacterial systems is less
understood. The purpose of this mini-review is to provide insights into heme metabolism
in bacteria. This paper is centered on the biochemical attributes of heme, heme
interactions that lead to toxicity, and the bacterial mechanisms for heme tolerance. A
special focus is given in this review to the group A streptococcus (GAS).

2.1

Iron, heme, and infection in mammalian systems.

Iron, the first-row transition metal, participated early in the evolution of life and to date
remains an essential element for the vast majority of organisms including bacteria. The
human body, for example, contains about 3-4 grams (gm) of iron. However, under
normal physiological conditions, iron that partitions within mammalian system is not
readily available (35, 36). Mammals have evolved multiple ways of sequestering iron in
both the extracellular and the cellular compartments not only to keep it soluble and
transferable but also to prevent the toxicity that is associated with the free metal. In
addition, since the majority of bacteria require about 10-6 to 10-7 M of iron for growth (37,
38), iron withholding also serves as a form of nutritional immunity in response to
infection.
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The extracellular fluids in the body are rich with oxygen and have a neutral pH. Under
these conditions, the iron is in the ferric form, which is extremely insoluble and therefore
must be bound to carrier proteins. The hepatic glycoproteins, transferrin and lactoferrin,
transport the ferric iron in the blood and body secretions (e.g. milk, tears, sweat, nasal
secretion, and saliva) respectively. The low solubility and the high binding affinity of
ferric iron to transferrin and lactoferrin (association constant of about 1036) leave the
interstitial fluids with an extremely low concentration of free metal [10-18 M] (39).
Transferrin-iron complexes circulate in the blood (with only 20-45% of transferrin
binding sites being filled) and the iron is eventually delivered to various cells by binding
to the transferrin receptors and subsequent endocytosis of the receptor-transferrin
complexes. In the intracellular compartment, most of the inorganic iron is stored in the
protein ferritin, which is mostly found in the cells of the liver and heart. It is heme
however, that represents the largest reserve of iron in the body (~80%). In the heme
molecule, the iron is coordinated by protoporphyrin IX (PPIX) that serves to solubilize
the metal and increases its catalytic activity by several folds (40). The majority of the
heme in the body is bound in hemoglobin and myoglobin, and found in erythrocytes and
muscle tissues (41). When heme and/or hemoglobin are released to the extracellular
compartment due to the lysis of erythrocytes or of other cells, heme components are
quickly bound by the carrier proteins hemopexin and heptoglobin and transported to the
liver for recycling.
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The daily iron requirements in humans are about 20-23 milligrams (mg). On average,
only 1–2 mg of dietary iron is absorbed daily. The recycling of iron reserves generally
from aging erythrocytes accounts for the rest of the metal iron (Figure 1). Iron recovery
from hemoglobin in senescent erythrocytes occurs in the macrophages of the lymphoid
tissues. A transporter named ferroportin mediates the export of iron from cells (such as
macrophages and the intestinal enterocytes) into circulation. Hepcidin, a peptide hormone
secreted by the liver, controls this process and therefore manages the overall extracellular
availability of iron (42, 43). Hepcidin functions by binding to ferroportin and causing its
eventual degradation.

In response to signals generated during infection processes, the liver secrets elevated
amounts of hepcindin, which in turn acts to reduce the export of cellular iron into
circulation. The liver also releases more hemopexin, heptoglobin to sequester heme and
hemoglobin from the serum. In addition, apo-lactoferrin is secreted by neutrophils and
macrophages are induced to enhance their uptake of iron and its further storage within
ferritin (44). Collectively, this response leads to hypoferremia, further reducing the
availability of iron at the extracellular compartment.

2.2

Heme.

Porphyrins (literal translation of Greek word porphura refers to the color “purple”) are a
universal class of heterocyclic compounds that support a myriad of biological processes.
The chemical composition of porphyrins can be best described as an aromatic, 16 carbon
atom ring scaffold which contains 4 nitrogen atoms obtained by the linking of 4
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tetrapyrrolic subunits with 4 methine bridges. This marcrocycle, utilizes inwards facing
nitrogen atoms to coordinate various metal ions forming secure metalloprophyrins
(Figure 2) (45). The stable complexes between transition metals cations and porphyrins
are attributed to the aromaticity of the heterocyclic compound. It is the porphyrin portion
that accounts for the increased solubility and catalytic activity in the biological systems
for the metal component. The high stability of the porphyrins with transition metals is
exemplified by Zn-tetraphenylporphyrin (ZnTPP), which has a stability constant of 1029
(46, 47). Iron-porphyrins (heme) are known for their redox reactions. Heme and hemeproteins have versatile biological functions including serving as sensors and transporters
of diatomic gases, biotransformation and detoxification of metabolites, chemical catalysis
(serving as a ‘source’ or ‘sink’ of electrons in redox reactions), and an important iron
reserve on which invading pathogen often rely (48).

The photoactive nature of porphyrin makes it a highly useful target in spectroscopy. The
chief characteristic absorption peak of protoporphyrins is around 380-400 nm (Figure 3).
This peak, known as the Soret or B-band, arises due to fully conjugated aromatic πsystem that allows transition from the ground state to a second excited state. The Q bands
are weaker absorbance peaks that occur after the Soret band. This region consists of a
weak transition of electrons to the first excited state and ranges between 500-750 nm
(49). Protonation of the inner nitrogen atoms of protoporphyrins, which occurs during
insertion of metal ions, causes strong changes in the visible absorption spectrum. Minor
variations in absorption spectrum can take place due to distal substituents. In addition, the
absorbance maxima are greatly influenced by the electronic state of iron, interactions
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with small ligands, and contact with amino acid side chains in the heme-binding pocket
or with axial ligands in a protein-bound heme. Figure 3 illustrates the various absorbance
spectra of free PPIX and heme as well as heme bound to the PefR protein of group A
Streptococcus. Holo-PefR depicts Soret absorbance between 404-430 nm and β, α bands
of heme absorb between 500-600 nm (50). Spectroscopic analysis provides a powerful
tool in analyzing the function of proteins and enzymes that use heme as a prostatic group
or cofactor. The ability to depict and monitor spectral behaviors has facilitated studies of
diverse reactions including heme binding, transfer, and degradation that have enhanced
our understanding of protein structures and functions.

2.3

Heme uptake.

With only few exceptions (e.g. Borrelia burgdorferi and some Lactococcal species), iron
is an indispensible micronutrient for all organisms. Successful colonization, therefore,
demands from invading bacteria to have means to obtain the nutrient iron from the host
environments. Consequently, bacterial pathogens often obtain iron from heme and have
evolved mechanisms to capture heme during infection. Gram-negative bacteria deploy
secreted hemophores or outer membrane receptors that can capture free heme or scavenge
it from host hemoproteins (such as hemoglobin and hemopexins). In both mechanisms,
the heme is delivered through the outer membrane and into the periplasmic space by Tondependent receptors using the proton motive force of the cytoplasmic membrane to
energize this process (51, 52). Hemophore-mediated uptake of heme for pathogenic
bacteria such as Pseudomonas aeruginosa, Yersinia pestis, and Hemophilus influenza has
been demonstrated (53-55). The outer-membrane receptors HmbR and HpuA of Neisseria

9

species and HutA of Vibrio Cholerae were shown to capture heme directly from host
proteins (56-58). In the periplasmic compartment, heme is captured by heme-binding
proteins and delivered across the inner membrane via dedicated ABC transporters, using
ATP hydrolysis to support the transport process.

Like Gram-negative bacteria, Gram-positive organisms also employ secreted hemophores
or dedicated surface receptors to capture heme from the extracellular milieu or to seize it
from the host hemoproteins. Nevertheless, significant differences in the nature of this
process and acquisition machinery exist, reflecting the differences in the cell envelope of
Gram-negative and Gram-positive organisms. Gram-positive bacteria are missing the
selective barrier provided by the outer membrane. On the other hand, the delivery of
heme to the cytoplasmic membrane has to overcome the challenge imposed by the thick
and dense Gram-positive peptidoglycan cell wall. A common approach that evolved
among Gram-positive organisms is the use of a protein relay apparatus that facilitates
heme shuttling from secreted hemophores or surface exposed receptors through the
peptidoglycan layers to heme-binding proteins in the cytoplasmic membrane. Not
surprisingly, the ABC-type transporters involved in this process are homologous to those
used by Gram-negative bacteria to mediate the transport through the cytoplasmic
membrane.

A few heme-capture and relay mechanisms have evolved independently among Grampositive organisms. The best understood machinery, named Isd (iron-regulated surface
determinant), was first described in Staphylococcus aureus. Orthologous systems have
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been recognized in a number of pathogens including Bacillus anthracis, Bacillus cereus,
and Listeria monocytogenes (59). Heme uptake by Isd-like proteins, involves a protein
module named NEAT (NEAr-iron Transporter), which is carried in one or more copies
by the Isd and Isd-like proteins. After it is captured by a NEAT domain belonging to
surface exposed Isd proteins, heme is relayed to the downstream NEAT domains of
proteins located deeper in the cell wall, until it reaches the cytoplasmic membrane (41,
60, 61). While in most cases, the Isd proteins are anchored to the cell wall; Bacillus
anthracis also employs NEAT-based hemophores, IsdX1 and X2, to capture labile heme
(61, 62). NEAT independent mechanisms of heme relay were described in
Corynebacterium diphtheriae (63) and Mycobacterium tuberculosis. However, the
molecular bases for the function of these receptors are not fully understood.

The major heme uptake pathway in GAS is named the streptococcal iron acquisition (sia)
system. The Sia machinery consists of 10-gene operon whose expression is directly
repressed by an iron and manganese-dependent repressor named MtsR (64, 65). The
streptococcal hemoprotein receptor (Shr) captures heme from hemoglobin via its NEAT
domains and transports it to the NEAT-like domain of the streptococcal hemoprotein
(Shp), which further delivers it to the binding protein SiaA (31, 33, 66). Other than the
presence of NEAT and NEAT like domains, Shr and Shp do not share homology to Isd
proteins, and unlike most Isd proteins they are anchored in the cell membrane instead of
the cell wall. The transport of heme through the cytoplasmic membrane is completed by
the membrane permease and ATPase encoded by the siaB and siaC genes respectively. A
second ABC transporter named streptococcal iron uptake system (siuABC) contributes to

11

GAS growth in iron-depleted medium supplemented with whole blood or hemoglobin
(30). However, heme binding or transport by the SiuABC was not directly demonstrated.

2.4

Heme degradation.

The recycling of iron from heme typically necessitates heme catalysis, which involves
oxidative cleavage by heme oxygenases (HOs). In addition to HOs being key components
in heme catabolism and iron homeostasis, these enzymes are associated with oxidative
stress management, the synthesis of light harvesting pigments phytobilin in plants, algae,
and cyanobacteria, and represent important iron acquisition pathways in bacterial
pathogens (67). The majority of the bacterial HOs are homologous to the mammalian
HO-1 enzyme. HO utilizes oxygen dependent reactions to cleave heme and generate
equimolar amounts of biliverdin (BV) IX, iron, and carbon monoxide (CO). In this
reaction heme acts as both substrate and a cofactor, and total of three oxygen molecules
and seven electrons are consumed during this reaction. The reducing equivalents for
heme catalysis are provided by NADPH (67).

Depending on the position of the eliminated carbon in the heme precursor, heme cleavage
can produce four possible isomers of BV, i.e. α, β, γ, and δ. In mammals and plants, HOs
preferentially initiate degradation at α -meso carbon to yield BV IXα (68). Degradation of
heme by HO is a multi-step process that in most cases proceeds with intermediates like
hydroxyheme and verdoheme to yield BV. In mammals, BV is further reduced by
biliverdin reductase (BVR) to yield bilirubin (BR) (Figure 4 and 5) (48). The productions
of BV, BR, and CO contribute to cytoprotection and have been targeted for developing
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therapeutics (69, 70). The fate and the purpose of BV that is generated during bacterial
heme catalysis are largely unknown, except for cyanobacteria (71). In eukaryotes, most
HOs use NADPH in conjunction with cytochrome P450-reductase (CPR) for the transfer
of electrons from NADPH. CPR is a flavin containing enzyme that facilitates the flow of
electrons from NADPH to FAD, from FAD to FMN, and finally from FMN to HO (and
cytochrome P450) (72). Bacterial HOs can use CPR, Trolox, ascorbate, and or
Ferrodoxin/Ferrodoxin reductase (for PigA, pa-HO, and BphO) as in vitro redox partners
(67). The identity of the native redox partners is unknown for most bacterial HOs [except
for pigA of P. aeruginosa, which can use pa-FPR for electron transfer during heme
catalysis (73)].

The most extensively studied heme oxygenases are the human HO-1 and HO-2 enzymes.
The gene encoding HO-1 is induced in response to iron limitations and other
environmental cues in most tissues with the exception of the liver and spleen. HO-2
expression is typically constitutive (48). As expected from enzymes involved in iron
supply, the vast majority of bacterial HOs are induced during growth in low iron
conditions. HO-1 is a large (~36 kDa) membrane bound protein. Most of the
characterized HOs in bacteria (including HemO, PigA, HmuO) share homology to HO-1.
These enzymes however, are missing the C-terminus anchor residues, and are therefore
smaller (~13-25 kDa) and located in the cytosol (67). The bacterial HOs that do not share
homology with the eukaryotic enzymes (such as ChuS from E. coli1 O157, IsdG/I from
S. aureus, MhuD from M. tuberculosis) are considered non-canonical. IsdG and IsdI from
S. aureus are examples from a non-canonical HO group that has a homodimeric β-barrel
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fold with two active sites at the dimer interface. Holo-IsdG shows significant ruffling
(non-planarity) of the bound heme leading to distortion in tetrapyrrole. Unlike most HOs,
IsdG catalyzes the liberation of one of the meso-carbons as formaldehyde instead of CO.
This reaction produces staphylobilin, an oxo-bilirubin chromophore rather than BV (7476). This unique chemistry implies not only different mechanism of oxygen activation
but also a distinctive evolutionary path of IsdG and related enzymes such as IsdI. The HO
of M. tuberculosis, MhuD, depicts heme-ruffling mechanism analogous to that of IsdG
family. However, MhuD produces an unusual product termed mycobilin, in which the
meso-carbon atom at the site of the ring cleavage remains attached as an aldehyde group
(77).

A new family of bacterial HOs with no sequence conservation to HO-1 was recently
identified. These enzymes include ChuZ of C. jejuni, HutZ of V. Cholerae, and HugZ of
H. pylori (78-80). Enzymes from this family have a putative FMN-like binding site with a
split β-barrel fold of homodimers. However, actual flavin binding is yet to be confirmed.
The non-canonical HOs are currently in the spotlight due to unusual heme coordination,
and production of unusual products with varied regiospecificity. GAS is able to thrive in
iron-restricted medium as long as it is supplemented with hemoglobin or other
hemoproteins. Heme utilization by GAS is quite evident but the catabolic enzyme(s)
remains to be identified. Notably, the GAS genome does not share homology to any of
the known canonical or non-canonical HOs.

2.5

The redox-active nature of heme.
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The machinery for heme uptake and degradation can supply bacteria with the growth
essential iron during infection. Paradoxically, this survival strategy can lead to cellular
damage, and the toxicity may be augmented when high levels of heme are encountered at
the infection site. The noxious effects of heme in bacteria are thought to be multifactorial.
Heme iron can participate in redox reactions that can in turn induce oxidative stress.
Oxidative stress occurs when the accumulation of free radicals exceeds the natural ability
of an organism to protect itself from radical damage. Heme is able to catalyze the
formation of reactive oxygen species (ROS) through multiple pathways (81). One of
these pathways, known as the Fenton reaction, which occurs when either ferric or ferrous
iron reacts with hydrogen peroxide (H2O2) to form hydroxyl radicals (OH) (82). This
process, which is cyclic in nature, is not only damaging by itself but can also lead to
initiation of vicious oxidative cascade due to interactions between the radical species and
various biomolecules. In humans, prolonged time spent in oxidative stress is related to a
multitude of disorders caused by damage to membrane lipids and proteins as well as
deficiencies in cellular signaling (83, 84). Studies have shown that hemin, the oxidized
version of heme, is cytotoxic due to its ability to aggregate in cell membranes and trigger
cell death (83). GAS showed heme-induced damages to membrane proteins, lipid
components, and chromosomes [(50), Eichenbaum unpublished data]. The prevention and
detoxification of heme stress is not well understood in most bacterial species. including
GAS.

2.6

Heme tolerance.
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Heme degradation carried by HO seems to be an obvious defense choice for bacteria.
(85). Sequestration of heme could be protective as well. In the Plasmodium parasite, free
heme is removed by the heme detoxification protein (HDP), which forms an innocuous
crystalized product called hemozoin (86). Sequestration of free iron by ferritin-like
proteins is quite common among bacterial species (63). In addition, various cytoplasmic
heme-binding proteins, such as HemS in Y. enterocolitica, function as interim heme
chelating agents before shuttling it to a dedicated HO for breakdown (87). Proteins
homologous to HemS that contribute to heme withholding and trafficking have been
described in other Gram-negative bacteria. These include the ShuS protein of Shigella
and the PhuS protein of Pseudomonas (88, 89). Active efflux is very useful in providing
protection from heme toxicity in mammalian systems. Transporters that pump a single
substrate (or a family of compounds) are considered dedicated transporters. Other
systems, which exhibit more promiscuous nature and are able to extrude structurally
distinct compounds, are referred to as multidrug resistance (MDR) efflux systems (90). It
is not uncommon for an MDR transporter to detoxify heme; for example the mammalian
feline leukemic viral receptor (FLCVR) and ABCG2 transporters confer heme tolerance
in erythroid cells by conducting the export of heme excess out of hepatocytes and
enterocytes in the gut lining (91). The MRP-5/ABCC5 MDR, which is known for
removing the monophosphate metabolites of fluorinated pyrimidine compounds in
metazoans is also essential in maintaining systemic heme homeostasis and in alleviation
of heme stress (92). For the majority of MDR transporters, ion motive force (H+ or Na+)
drives the pumping mechanism, but there are increasing evidences for reliance on ATP
hydrolysis in heme efflux as well (93).
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Among bacterial systems, S. aureus, group B streptococcus (GBS), and B. anthracis
combat heme toxicity by export. These pathogens encode the heme-regulated
transporter, HrtAB, which pumps heme (at levels of 1-10 M) and or toxic by-products
of heme catabolism (94, 95). The regulatory network that controls heme tolerance in
bacteria varies among different species. For example, the expression of the hrtAB genes
in the pathogenic S. aureus, B. anthracis, and C. diphtheria is responsive to the twocomponents, HssSR, system. The non-pathogenic L. lactis, utilizes HrtR, a TetR family
of regulator in heme hemostasis (96). In addition to putative hrtAB genes, the
opportunistic GBS employ a five-gene regulon that is referred to as ‘porphyrin-regulated
efflux (pef) in managing the intracellular pools of heme and PPIX (95). A MarR-like
protein, named PefR, repressed the pef regulon in a heme dependent manner. PefR
disengages from its cognate operator sites upon binding to heme or PPIX. The pef
regulon is expressed in response to lower levels of heme (0.1-10 M) than the putative
hrtAB genes (10 M), and is thus proposed to function in the fine-tuning of intracellular
heme levels. Knockout strains of hrtAB and pef systems are ultrasensitive to heme
exposure, an observation that highlights a critical and an intricate regulatory mechanism
for heme tolerance in pathogenic strains (95). Exporters from the general multiple
transferable-resistance (mtr) family were also implicated in providing protection from
heme stress in S. aureus and GBS (97).

In GAS, we have recently shown that the transcription of a pefRCD-like operon is
induced in response to environmental heme and demonstrate that the putative repressor,
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PefR, specifically binds heme and PPIX in-vitro. In-silico analyses revealed a high
degree of conservation of the Pef proteins among the 20 GAS genomes that are available
in the database. In addition, the genomic organization of the pef locus is conserved
among the streptococci from the pyogenic cluster (S. pyogenes, S. agalactiae, S. iniae,
and S. equi). In vivo data collected with strains defective in functional pefCD genes
illustrated an increased sensitivity to heme and anthracyclic compounds. Additionally, the
lack of the PefCD proteins in GAS leads to increased heme-induced damage in lipids and
DNA (Eichenbaum unpublished data, chapter 4). Thus, the pef system is the first type of
efflux system linked to heme tolerance in GAS. Now, that we have established that labile
heme causes cellular mayhem in GAS and GAS employs activation of protective
pathways including pef system; it would be noteworthy to examine the mechanisms of
pathogen heme-sensing and tolerance used during host infections.
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3

CHAPTER 2- IN VITRO HEME BIOTRANSFORMATION BY THE HUPZ
ENZYME FROM GROUP A STREPTOCOCCUS

3.1

Introduction

Most of the iron in mammals is bound to protoporphyrin IX in heme molecules, which
are found in complex with hemoglobin, myoglobin, and other proteins. Pathogenic
bacteria often tap into the heme reservoir to overcome the severe iron scarcity, which
they encounter during infection. These pathogens use elaborate systems to scavenge
heme from host hemoproteins and transport it into the bacterial cell (41, 98-100). A few
mechanisms allow bacteria to retrieve iron from heme. For example, the release of iron
from heme without breaking the macrocyclic ring by enzymes belonging to the family of
dye-decolorizing heme peroxidases (DyP) has been described in Escherichia coli (101)
and Staphylococcus aureus (102). The most common pathway, however, relies on
oxidative cleavage of the porphyrin ring by enzymes known as heme oxygenases (HOs)
(103, 104). When supplied with oxygen and electron donors, canonical HOs (e.g., HO-1
in eukaryotes) break down heme through three sequential mono-oxygenation steps (105).
In the first step, heme is reduced to the ferrous form and rapidly binds oxygen. A
subsequent reduction and protonation generates ferric hydroperoxy species, which selfhydroxylate the tetrapyrrole at one of the meso carbons forming a hydroxyheme
derivative (-meso-hydroxyhemin). In the second step, the hydroxyheme reacts with
another oxygen molecule and is converted to verdoheme with the release of a meso
carbon as carbon monoxide (CO). In the third and rate-limiting step, the cyclic
verdoheme is opened through a reaction with oxygen, producing biliverdin and iron. Like
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HO-1, many bacterial HOs specifically hydroxylate the porphyrin at the -meso carbon
and eventually produce -biliverdin. Some bacterial enzymes however, demonstrate
different regiospecificity and produce alternative or a mixture of biliverdin isomers (103,
104).

The first bacterial HO to be discovered was HmuO, a homologue of the human HO-1
enzyme found in the pathogen Corynebacterium diphteriae (106, 107). Other HOs that
also show significant structural and functional similarities to HO-1 were identified and
characterized in several bacteria including Neisseria meningitidis (HemO) (108, 109),
Clostridium species (HemO) (110, 111) and Pseudomonas aeruginosa, PigA (pa-HO or
HemO), and BphO (112, 113). Like the mammalian enzymes, these bacterial HOs have a
single compact domain that consists mostly of α-helices, with the heme inserted in
between two of the α-helices (104). These bacterial enzymes degrade heme to αbiliverdin, with the exception of PigA, which produces a mixture of β- and δ-biliverdin
isomers (112-115). Most of the characterized HOs in bacteria are associated with iron
acquisition and are negatively regulated by iron (41, 116). BphO, however, appears to be
an exception as it is expressed independently of iron availability and serves only to
produce the precursor for the phytochrome chromophore (113-115).

Bacteria also use HOs that evolved independently of HO-1 like proteins; ChuS from E.
coli O157:H7, for example, is such a non-conventional HO (117). ChuS has a unique
structure that consists of two central sets of antiparallel β-strands, each flanked by two
pairs of α-helices (117). Several cytoplasmic heme-binding proteins share sequence
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homology with ChuS including HemS from Yersinia enterocolitica (87, 118), Bartonella
henselae (119) and PhuS from P. aeruginosa (120). However, heme degradation was
demonstrated only for a few family members (117, 119). In addition, it has been
established that PhuS does not degrade heme and instead specifically delivers its heme to
a partner HO (120, 121). Therefore, different proteins from this group may function in
intracellular heme trafficking rather than in direct degradation of heme.

IsdG from S. aureus is the prototype of a non-canonical HO group that has a distinctive
homodimeric β-barrel fold with two separate active sites at the dimer interface (74, 122).
IsdG catalyzes heme degradation by liberating one of the meso carbons as formaldehyde
instead of CO; this reaction produces an oxo-bilirubin chromophore (staphylobilin) rather
than biliverdin (123, 124). The unique catalytic mechanism of IsdG is attributed to the
ruffling of the bound heme molecule and its impact on the chemistry of oxygen activation
(123). S. aureus encodes two representatives of this family, IsdG and IsdI (74). Other
members of the IsdG HO family include HmuD and HmuQ from Bradyrhizobium
japonicum (125), IsdG homologues from Bacillus anthracis (75) and S. lugdunensis
(126). MhuD from Mycobacterium tuberculosis is another HO related to IsdG with heme
ruffling and which also degrades heme without CO release. However, MhuD produces a
novel product named mycobilin, in which the meso-carbon atom at the site of the ring
cleavage remains attached as an aldehyde group (77, 127).

A new family of bacterial HOs with no homology to previously described enzymes was
recently uncovered in Campylobacter jejuni (ChuZ) (78), Helicobacter pylori (HugZ)
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(80, 128) and Vibrio cholerae (HutZ) (79, 129). Proteins from this family form
homodimers with a split β-barrel fold that is characteristic of FMN-binding proteins, but
no FMN binding was demonstrated. Interestingly, like PigA, HugZ exhibits δ-meso
regiospecificity for cleaving the ring in the heme molecule (80), whereas HutZ is
suggested to have β- or δ-meso regioselectivity (79). The exact nature of the bilin
produced by HutZ or ChuZ reactions were not defined.

The Group A Streptococcus (GAS) is a significant human pathogen that produces an
array of clinical manifestations including infections of the mucosal membranes and the
skin that are typically moderate, severe invasive infections, as well as post-infection
sequelae (4, 130). GAS is a hemolytic bacterium that readily uses hemoglobin and other
hemoproteins to satisfy its need for iron (131). A heme relay apparatus comprising Shr,
Shp, and SiaABC (HtsABC) proteins mediates the capture and delivery of heme into
GAS cell (32, 132-135). A second ABC transporter, SiuADBG, also contributes to heme
acquisition in GAS through an unknown mechanism (30). Heme uptake is important for
GAS pathogenesis and adaptation to the host environment. Accordingly, mutants in shr,
sia or siu genes are attenuated for virulence (30, 31, 136).

Despite the strides made in the field of heme uptake in Gram-positive bacteria, the
mechanism for heme catabolism and iron release remains unknown in GAS and the
Streptococcus genus. Herein, we provide biochemical evidences for in vitro heme
binding and degradation by HupZ. Moreover, our structural and bioinformatics data on
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HupZ, suggest that this streptococcal protein represents a new split β-barrel enzyme
functioning in heme biotransformation.

3.2

Materials and Methods

3.2.1

Bacterial strains, media and antibiotics

E. coli cells were grown aerobically, in Luria–Bertani (LB) medium at 37 °C
supplemented with 100 µg/ml of ampicillin. In certain experiments cells were grown in
the presence of 25 µg/ml of 5-aminolevulinic acid and 25 µg/ml of ferrous sulfate at 37
°C under shaking conditions. The E. coli strains used in this study are listed in Table 1.

3.2.2

Recombinant HupZ

The hupZ gene was amplified from GAS using the pair of primers, ZE437ATGATAACACAAGAAATGAAA / ZE438- GTTACTTTCACTGTTTATTTCTT. The
plasmids used in this study are listed in Table 1. The construction of HupZ-His
expression vectors was accomplished by TOPO® directional cloning according to the
manufacturer instruction (Invitrogen, K101-01). The hupZ gene was amplified from GAS
NZ131 chromosome using the ZE437/ZE438 primer set and introduced into the
pET101/D-TOPO vector. The resulting plasmid, pZZ2, codes for a HupZ-His tag fusion
protein expressed from the T7 RNA polymerase promoter.

3.2.3

Protein expression and purification

Expression of the recombinant His-tagged proteins was induced overnight at 27 °C (or 5
hours at 37 °C) with 1 mM isopropyl β-D-1-thiogalactopyranoside. Cells were harvested
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and re-suspended in an extraction buffer (20 mM Tris-HCl, pH 8.0, 100 mM NaCl, 0.1%
Triton X-100) with the addition of 0.5 mg/mL Complete, mini-EDTA-free protease
inhibitor cocktail tablets (Roche), then lysed by sonication. The cells’ pellet was
centrifuged and the cleared lysate was then applied to a 5 mL HisTrap HP affinity
column (nickel column) and purified using a FPLC. Purified protein was dialyzed in
sodium phosphate buffer (SPB, 20 mM sodium phosphate, 500 mM NaCl, pH 7.4) prior
to its use for experiments. Western blot analysis of the recombinant His-tagged protein
was carried out using anti-His antibodies from mouse (Sigma).

3.2.4

Heme reconstitution

Heme reconstitution experiments were conducted as described in (134). Hemin chloride,
the oxidized form of heme, was used in all experiments. For simplicity, in this manuscript
we refer to iron-protoporphyrin complex in both redox states as heme.

3.2.5

Heme degradation assays

Heme-HupZ complex was prepared at a heme:protein ratio of 1.5:1 and excess heme was
removed by filtration through a PD-10 column (GE Healthcare). Degradation of bound
heme by HupZ was carried in the presence of NADPH [with NADPH regeneration
system for heme degradation (Figure 7B) and iron release (Figure 9) or without
regeneration system for heme degradation (Figure 7A) and the detection of CO (Figure
8)] and human NADPH-cytochrome P450 reductase (CPR) or ascorbic acid. Ascorbic
acid was added to a final concentration of 20 mM. In the NADPH-CPR system, hemeHupZ protein (20 µM) was added to 0.4 μM of recombinant CPR. The reaction was
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initiated by adding 100 μM of NADPH to the system and spectra were recorded from 250
nm to 700 nm every 10 min for 1 h and every 60 min for additional 5 hours. Catalase
(bovine liver, Sigma-Aldrich) was added to the reaction systems at a final concentration
of 2 μM. The heme degradation reaction with ferredoxin reductase (FNR) and ferredoxin
(Fdx) typically contained 20 M Holo-HupZ, 10 M Fdx, 0.1 unit/mL spinach FNR, 2
M catalase and 500 M NADPH, in 1 mL SPB. The UV-visible absorption spectra were
recoded before and at 10, 20, 30, 50 and 60 min after the addition of NADPH.

3.2.6

Myoglobin differential spectroscopy

5 M holoHupZ, 2 M catalase, 0.4 M CPR were mixed in 20 mM sodium phosphate
buffer, pH 7.4, containing 500 mM NaCl. The reaction mixture was used as the blank and
4 M of myoglobin solution was added immediately to the reaction. The UV-visible
absorption spectrum of myoglobin was acquired over 16 min at 30 s intervals where
reaction was initiated by the addition of 500 μM NADPH. The reference reaction was
carried out similarly, except that instead of holoHupZ an equal volume of buffer was
added, blanked, prior to adding 4 M of myoglobin and 500 μM NADPH. The reaction
was carried out at 25 °C.

3.2.7

Ferrozine differential spectroscopy

20 M of holoHupZ, 2 M catalase, 200 M NADPH, 6.5 mM glucose-6-phosphate, 1
unit/mL glucose-6-phosphate dehydrogenase, 0.4 M CPR and 1 mM ferrozine were
mixed and the reaction was followed for several hours (spectra were recorded frequently
for the first hour; then every 60 min for a total 5 hours. One time point was taken after 22
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h). The reaction was carried out at 25 °C in a final volume of 750 L. The reaction was
blanked with catalase, glucose-6-phosphate, glucose-6-phosphate dehydrogenase, CPR
and ferrozine in 50 mM MOPS buffer containing 500 mM NaCl (pH 7.4).

3.2.8

Crystallization and data collection

Crystals of HupZ were grown in hanging drops at room temperature by mixing 1 L of
protein solution (6 mg/mL of protein) and 1 L of reservoir solution (20% PEG 3350, 0.2
M lithium acetate). The crystals were cryo-cooled with a cryo-protectant containing 22%
glycerol in addition to the mother liquor. The X-ray diffraction data were collected at 100
K on beamline 22-ID of the Southeast Regional Collaborative Access Team (SER-CAT)
at the Advance Photon Source, Argonne National Laboratory. The data were integrated
and scaled with HKL2000 (137).

3.2.9

Structure determination

The crystal structure of HupZ was solved by molecular replacement employing PHASER
(138, 139). The published structure of putative pyridoxamine 5-phosphate oxidase
(PNPOx, PDB ID: 2HTD) sharing 28% sequence identity with HupZ was used as the
initial model. Successful structure solution was obtained by pruning the N-terminal eight
residues of the initial model and also using serine instead of the dissimilar amino acids in
the HupZ sequence compared with the 2HTD sequence. The HupZ structure was
constructed from the molecular replacement phases using the Arp/wArp program (140,
141), which fitted 84% of the amino acid residues into the electron density. The model
was subjected to several rounds of refinement in REFMAC (142) and the rest of the
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protein structure was manually built with COOT (143). Solvent molecules were inserted
at stereochemically reasonable positions using 2Fo-Fc and Fo-Fc maps at 1 and 3 sigma
levels, respectively. The Rwork and Rfree values of the final refined structure are 17.0 %
and 21.7 %, respectively. The data collection and refinement statistics are summarized in
Table 2. The final refined structure has excellent protein geometry with no disallowed
/ values on the Ramachandran plots. Structures were superimposed by secondary
structure matching using SUPERPOSE (144) in CCP4 suite. The HupZ crystal structure
was deposited with PDB ID 4NU4.

3.3

Results

3.3.1

HupZ is a new heme binding protein

GAS growth in an iron-depleted medium is restored when the medium is supplemented
with whole blood or various heme-containing proteins, indicating that the hemolytic
pathogen can retrieve iron from heme (30, 32, 131, 134). Yet, bioinformatics analysis
failed to locate homologs of characterized HOs in the GAS genome, suggesting that a
new type of enzyme may be involved. In a recent microarray analysis we identified a
putative gene (spy49_0662) that is repressed by MtsR, the global iron-dependent
regulator of GAS (65). Spy49_0662 encodes a 15.9 kDa ORF containing the signature
domain of PNPOx, found in FMN binding enzymes and evidently without any secretion
signals. We therefore hypothesized that the iron-repressed spy49_0662 encodes a
cytoplasmic enzyme involved in iron metabolism.
To begin testing the function of Spy49_0662, we cloned and purified it from E. coli as a
C-terminal end fusion to hexa-histidine tag. SDS-PAGE and Western blot examinations
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revealed the presence of a single protein band that migrated to the expected size (Figure
6A) and reacted with anti-His tag antibody (data not shown). UV-visible absorption
spectrum of the purified protein did not exhibit significant absorption other than at 280
nm (apo-HupZ, Figure 6B). However, when the HupZ was purified from cells grown in
the presence of the heme precursors, 5-aminolevulinic acid and iron, it had a brown color
and UV-visible scanning suggested that it was bound to heme (Figure 6C). To test if
indeed heme serves as a ligand for Spy49_0662, we incubated it with heme (30 min at
1:1.5 molar ratio, pH 7.4). After excess heme was removed, Spy49_0662 demonstrated
absorption peaks at 414, 530, and 560 nm characteristic of a heme-bound protein (HemeHupZ, Figure 6B). The absorption maximum at the Soret region (390-430 nm) and the 
and  bands (500-600 nm) exhibited by Spy49_0662 following incubation with heme are
indicative of heme-protein complex formation and are clearly distinguishable from the
spectrum of free heme in solution (Free heme, Figure 6B). Heme binding by Spy49_0662
was investigated further by titration of the apo protein with increasing amounts of free
heme. A growing Soret band at 414 nm appeared in the resultant solution with
incremental addition of heme (Figure 6D). The plot of the differential absorbance at 414
nm as a function of heme these data established that spy49_0662 encodes a protein that
specifically binds heme. We therefore named Spy49_0662 as HupZ (for heme utilization
protein). The molar extinction coefficient for heme-bound HupZ was determined at 414
nm using the pyridine hemochromogen method (145) and resulted in ε414 nm = 110,000 M1

cm-1.
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3.3.2

Heme degradation by HupZ proceeds with the production of CO, ferrous
iron, and a chromophore that absorbs at 660 nm

Heme binding by HupZ, a likely cytoplasmic protein, supported the notion that it may be
involved in heme trafficking or metabolism. We therefore asked if HupZ is capable of
heme degradation. Oxidative cleavage of heme by HOs requires a source of reducing
equivalents, which is provided in mammals by NADPH and CPR (146). While the native
redox partner for most bacterial HOs is unknown, CPR is typically used to support heme
catabolism by these enzymes in vitro. Heme degradation by holoHupZ was assessed first
in a reaction containing human CPR and NADPH as reductants. The reaction was
incubated at room temperature and the change in the UV-visible absorption spectrum was
recorded at 10 min intervals for 1 hour (Figure 7A). Catalase was included in the
reactions to prevent non-enzymatic degradation of heme by hydrogen peroxide. As
shown in Figure 7A, the absorbance at 414, 530, and 560 nm decreased over time. The
absorption peak at 340 nm, which is indicative of NADPH, also decreased rapidly during
incubation (Figure 7A), suggesting that the pyrimidine nucleotide may be a limiting
factor in the catalysis under our experimental conditions. We therefore included an
NADPH regeneration system consisting of glucose 6-phosphate and glucose-6-phosphate
dehydrogenase in the reaction (147). This addition allowed us to follow heme
degradation without exhausting the NADPH (Figure 7B). Although the decrease in the
Soret region was more rapid in the first 10 minutes, the Soret band continued to decrease
for two-three hours. A growing peak at 660 nm followed the drop in the Soret peak and
became more pronounced during the second hour of incubation (Figure 7C). Importantly,
no significant spectral changes were observed during incubation of either free heme or a
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control hemoprotein (holoShp) in the reaction buffer, indicating that heme in solution or
in complex with protein does not react with NADPH under our experimental conditions
(Figure 7D). The changes in the spectral properties of holoHupZ (during incubation with
NADPH and CPR) imply that this enzyme progressively degrades the bound heme to
form a product that absorbs at 660 nm. Our studies also show that human CPR can serve
as an in vitro redox partner of HupZ. Some bacterial HOs can use alternative redox
partners such as Fdx, FNR and/or ascorbate. We found however, that the inclusion of
spinach Fdx and FNR or ascorbic acid instead of CPR in the HupZ reaction did not lead
to spectral changes (Fig. 8 and data not shown).

While canonical HOs release one of the meso carbons as CO during heme degradation,
two bacterial enzymes were recently reported to catalyze heme breakdown by alternative
mechanisms that involve the release of formaldehyde instead of CO (123) or the retention
of the carbon atom after the ring cleavage (77). To test for CO formation by HupZ we
used an established method that relies on the spectral signature of myoglobin-CO
complex (107) and monitored the differential absorption spectrum of myoglobin during
heme degradation. Myoglobin affinity for CO is 200 times higher than that for dioxygen
(148), therefore if CO is released during heme breakdown in the presence of myoglobin it
is likely to be captured. As can be seen in Figure 9, a shift in the absorption maximum
from 410 to 420 nm was observed during the reaction. This spectral change was
accompanied by the appearance of bands at 540 and 580 nm. The generated peaks at 420,
540 and 580 nm are characteristic of myoglobin-CO complex (107). The plot of the
absorbance at 410 and 420 nm as a function of time, demonstrates the conversion of the
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starting myoglobin state (ferrous-dioxygen) to myoglobin-CO complex during the
reaction course (Figure 9, insert). No changes in the spectrum of myoglobin were
observed in control reactions without holoHupZ (Figure 9 insert, control reaction).
Together, these experiments indicate that like the canonical enzymes, HupZ generates
CO as one of the reaction products.

To test whether HupZ releases iron from heme, we used the iron-indicator ferrozine.
Ferrozine forms a stable magenta-colored solution with the ferrous iron, which exhibits a
single sharp peak with maximum absorbance around 564 nm (149). Differential
spectroscopy of HupZ catalysis of heme degradation in the presence of ferrozine
demonstrated that the decrease in the Soret peak at 414 nm was accompanied by the
concomitant increase of a peak at 564 nm, suggesting the formation of iron-ferrozine
complex (Figure 10A). When free heme was incubated with ferrozine under the same
conditions, no significant changes in absorbance were noticeable even after a long
incubation period (Figure 10B). This observation indicates that ferrozine is able to
capture iron only from solution but not from intact heme molecule. Using a standard
curve, we determined that 20 M holoHupZ generated about 20 M iron over the course
of the reaction, suggesting complete degradation of the bound heme (Fig. 10C).

3.3.3

Crystal structure of HupZ

HupZ was crystallized in the triclinic space group of P1 with two dimers in the unit cell.
The crystallographic data and refinement statistics are summarized in Table 2. The
structure was refined to the resolution of 2.0 Å with R and Rfree of 16.7 and 20.8,
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respectively. The final structure has 119 residues per monomer with good electron
density. Fourteen residues at the C-terminal end are disordered in the electron density
maps and cannot be modeled unambiguously. The asymmetric unit consists of two HupZ
homodimers (Figure 11A). All four monomers are essentially identical and can be
superimposed with low pairwise RMSD values of 0.2-0.4 Å. The two dimers also
superimpose with a very low RMSD of 0.2 Å, and the description here forth applies to
both the dimers. The structure of the HupZ monomer contains six β strands, three 
helices and forms a typical split-barrel fold (Figure 11B). The six strands form an
antiparallel -barrel. The first two helices lie across and block the two open ends of the β
barrel. The third helix is packed against the side of the  barrel. HupZ dimerizes by
stacking the β-barrel from two monomers at an angle of ~90.

The new HupZ crystal structure was compared with known structures of other bacterial
HOs. Comparison of HupZ with HugZ (128) [PDB ID: 3GAS], an HO from H. pylori,
shows that the two dimers can be superposed by secondary structure matching to give an
RMSD of 2.5 Å for 218 C atoms. HupZ is smaller and lacks the 80 residues N-terminal
domain of HugZ, but the two proteins share the same split barrel fold for the C-terminal
domain (Figure 11C). A heme moiety was observed in HugZ bound at the dimer
interface, where it mainly interacts with the C-terminal residues. The flexible C-terminal
region of HugZ plays an important role in heme binding and in particular His245 is
involved in heme iron coordination and is conserved in related heme-utilization proteins
(128). HupZ has a shorter C-terminal region that is truncated by 28 amino acids
compared to HugZ. In addition, HupZ has no histidine in the superimposed structures
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corresponding to His245 that coordinates heme iron in HugZ. In fact, the only histidine
present in the HupZ sequence is located at the surface of the monomer and distal from the
dimer interface. HugZ bears Arg166, which forms a water-mediated interaction with
heme iron coordinating azide, and is essential for its activity (128). Substitution of
Arg166 to Ala in HugZ results in loss of HO activity of HugZ. However, the amino acid
structurally equivalent to Arg166 in HupZ is a glycine, which cannot form the equivalent
interactions. The absence in HupZ of these crucial amino acid residues in HugZ
emphasizes differences in the heme binding mechanism of the two enzymes.

Comparison of HupZ with ChuZ (78) [PDB ID: 3SWJ] another HO from C. jejuni, shows
that the monomers from the two structures can be superposed to an RMSD of 2.2 Å for
108 C  atoms based on secondary structure matching. Similar to HugZ, ChuZ has a
smaller 82 residue N-terminal domain, which is absent in HupZ, and a larger 169 residue
C-domain with a split barrel fold resembling those in HugZ and HupZ (Figure 11D). The
ChuZ crystal structure contains two bound heme molecules. The first heme binds at the
dimer interface and is coordinated by His245 at the flexible C-terminal loop as seen in
HugZ. The azide coordination of the other side of this heme and water mediated
interaction with Arg166 are also conserved in ChuZ and HugZ indicating a common
heme binding and reaction mechanism for these two enzymes. However, the ChuZ
structure features a second surface heme bound to the N-terminal domain through
residues His9 and His14. Alanine mutation of these two surface histidines together with
Arg166 eliminates the heme degradation activity of ChuZ by blocking heme binding at
the dimer interface and the non-enzymatic oxidation of the surface bound heme. His9 and
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His14 of the N-terminal domain are conserved in both ChuZ and HugZ, which also
indicate a conserved binding site. No equivalent histidines are present in HupZ,
suggesting a different mechanism for heme binding.
The third heme degrading protein with a split barrel fold, HutZ (79, 129) [PDB
ID: 3TGV] from V. cholerae also can be superimposed with HupZ to an RMSD of 2.1 Å
for 218 C atoms in the dimer by secondary structure matching. However, the HutZ
crystal structure has no bound heme. Also, the first 12 residues at the N-terminal end and
25 residues in the C-terminal end including the heme-Fe coordinating His were removed
during cloning to prevent crystal twinning observed with the full length protein. Hence,
this HutZ structure can yield little information on heme binding.

3.4

Discussion

Previous studies established that GAS uses dedicated surface receptors and membrane
transporters to capture heme from host hemoproteins and relay it through the
peptidoglycan layers and into the cytoplasm (30, 32, 132-135). GAS imports heme to
satisfy nutritional requirements for metal iron (131, 134). Bacteria typically employ
cytoplasmic HOs to release the iron from the porphyrin center. These enzymes catalyze
the oxidative cleavage of one of the porphyrin meso carbon bridges at α, β, γ or δ
positions and usually produce free iron, CO, and biliverdin (103, 104). To date, no HOs
have been identified in GAS and the fate of the imported heme remained obscure. In this
study, we describe a new GAS enzyme, HupZ, which binds and degrades heme in vitro.
The recombinant HupZ can be isolated from E. coli in the apo form, which readily binds
exogenous heme to saturation at a 1:1 ratio (Figure 6B and 6C) or in complex with heme
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(after growth in medium containing 5-aminolevulinic acid and iron) (Figure 6D). The
addition of NADPH to heme-bound HupZ (in the presence of CPR and NADPH
regeneration system) triggered a progressive decrease of the protein absorption at the
Soret region, 530, and 560 nm with an absorption peak at 660 nm (Figure 7). These
spectral changes suggest the conversion of the heme bound to HupZ to a bilin that
absorbs at 660 nm. Since catalase, which can scavenge hydrogen peroxide that may be
produced in the reaction, was included in all reactions, catalytic conversion of the heme
rather than coupled oxidation is responsible for the observed changes in the absorption
spectrum. The absence of similar changes in reaction samples containing heme, free or
bound to Shp, without HupZ shows that HupZ is required for this conversion.

Spectroscopic assessment of myoglobin-CO complex formation during the HupZ reaction
confirmed the release of CO from heme by HupZ (Figure 9) and suggests that HupZ
heme degradation proceeded through the first two steps of a typical HO reaction. The last
step in a standard HO reaction involves protonation and reduction of the iron in the
ferric-biliverdin complex, which does not have significant spectroscopic features to
produce free ferrous iron and biliverdin (which absorbs at the 640 to 680 nm range) (104,
105, 150). The formation of the broad band at 660 nm by the HupZ reaction suggests
therefore that this enzyme is able to carry on and liberate the iron. The demonstration of
ferrous iron release is provided by titration with ferrozine. The magenta color and the
band at 564 nm formed during the reaction indicate the formation of ferrozine-iron
complex (Figure 10). Moreover, a direct correlation between heme consumption and the
development of the ferrozine-iron complex was observed. Together, these observations
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suggest that HupZ degrades heme in the presence of reducing equivalents (NADPH and
CPR) and produces CO, ferrous iron, and an unidentified chromophore. Moreover, CO
production implies that the catalytic mechanism of HupZ follows the canonical pathway
and not those mediated by IsdG- or MhuD-type enzymes (77, 124).

While HupZ quantitatively liberates iron from heme, this reaction is very slow and takes
several hours to complete under our experimental conditions (Figure 9). Difficulties in
releasing iron from the linear tetrapyrrole in vitro were reported for several HOs (73, 107,
114, 124). The efficiency of this final step in heme catalysis often appears to depend on
the nature of the redox partner. For example, in the presence of ascorbate, the human HO1 enzyme produces ferric-biliverdin complex and not free iron as it does with NADPH
and CPR (150). The HO-1 like enzyme from C. diphtheriae (HmuO) catalyzes the
formation of biliverdin and free iron with either NADPH/CPR or ascorbate. With
ascorbate, however, the last step of the reaction is slow. Free biliverdin is observed only
after two hours of incubation (107). Finally, many bacterial HOs cannot reduce and
liberate the iron in vitro and thus catalyze the formation of ferric-biliverdin complex as
the final product. These include HemO from N. meningitidis (109), BphO from P.
aeruginosa (73), PigA from Pseudomonas species (114), and HutZ from V. cholerae
(79). Considering the absence of sequence homology between HupZ and HO-1, it seems
likely that the interactions between HupZ and the eukaryotic CPR are inefficient which
may explain the sluggish iron release. Fdx/FNR or ascorbate could not support heme
degradation by HupZ under our experimental conditions (Figure 8 and data not shown).
Therefore, at this time, only NADPH/CPR was demonstrated to drive HupZ catalysis in
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vitro. The identity of the cognate redox partner of HupZ remains elusive. The use of
cognate redox partner in the HupZ reaction instead of CPR may allow for more efficient
heme degradation in vitro, as was seen with the IsdI and IsdG enzymes while paired with
IruO, their probable redox partner in vivo (151).

HupZ does not share significant sequence homology with characterized HOs. To
gain molecular insights into this new enzyme we solved the crystal structure of HupZ.
The apo protein was crystallized as a homodimer with a split β-barrel conformation in
each monomer, which contains six β strands and three α helices (Figure 11A). The
structure of HupZ is similar to the common structural domain shared by the ChuZ, HugZ
and HutZ proteins (Figure 11B-C) (78, 128, 129). Despite the overall structural
resemblance, several important differences occur between HupZ and HOs from this
family. HupZ is smaller and lacks the 80-residue N-terminal of HugZ and ChuZ, which is
proposed to mediate coupled oxidation of heme (78). In addition, HupZ lacks the heme
iron coordinating histidine residue (His245) that is conserved in both ChuZ and HugZ.
The corresponding His170 in HutZ, however, was found to be unnecessary for heme
binding (129). A phylogenetic tree was generated from the multiple sequence alignment
of several HOs from various organisms (Figure 12). Members of the different families of
HOs were grouped with their known respective relatives with high bootstraps values for
the external nodes. This analysis located HupZ to a branch that is separated from the
other HOs, indicating it belongs to a new subfamily of split β-barrel enzymes. The low
bootstraps values for the internal nodes suggest that the bacterial HOs evolved
independently and that this tree does not reliably represents the evolutionary direction of
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this process. Putative ORFs that are homologous to HupZ are found in the genomes of
GBS, Streptococcus dysgalactiae and other streptococci suggesting that HupZ is possibly
a representative of a new family of enzymes in Streptococcus species.
In conclusion, we identified a new streptococcal enzyme that degrades heme in
vitro generating CO, free ferrous iron, and unidentified chromophore. HupZ adopts a split
β-barrel fold, thus it structurally resembles members of a recently characterized family of
bacterial HOs. The structurally related HugZ produces δ-biliverdin, but final product of
ChuZ and HutZ remained to be described (79, 80, 152). The significant differences
observed between HupZ and these bacterial HOs indicate that HupZ may be a
representative of a separate family of bacterial enzymes. The vast majority of HOs in
bacteria are associated with iron uptake. Regulation by a metalloregulatory protein (such
as Fur or DtxR) is one of their hallmarks (41, 116); other than BphO, the expression of
bacterial HOs enzymes is enhanced during growth in low iron conditions. Likewise,
MtsR, the global metal-dependent regulator in GAS represses the expression of hupZ
gene [spy49_0662] (65). Regulation by iron availability supports the notion that HupZ
degrades heme to provide GAS with iron. However, further analysis is necessary to
unequivocally determine the role of HupZ in GAS physiology.
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4

4.1

CHAPTER 3- HEME TOXICITY AND TOLERANCE IN GAS

Introduction

Heme is vital to many biological systems, ranging from planktonic marine
microorganisms to the highly complex and evolved humans. The heterocyclic ring in
heme, protoporphyrin IX (PPIX), co-ordinates metal iron (Fe+2); this architectural
arrangement supports a wide array of roles upon presentation of an appropriate
microenvironment. Hemoglobin and myoglobin, for example, use heme as a prosthetic
moiety for the transport and storage of oxygen and other diatomic gases. A multitude of
redox enzymes engages heme as a catalyst of electron transfer. Heme is also associated
with energy conservation and biotransformation in processes such as photosynthesis and
respiration. In addition, signal transduction pathways are integrated via heme due to its
ability to bind gaseous ligands such as oxygen, carbon dioxide, carbon monoxide, and
nitric oxide (81, 153, 154). Notably, heme in hemoproteins constitutes a major iron
reserve used by invading microorganisms during infection (41, 155). Blood in particular
is an immediate source of iron and heme for the majority of pathogens. Invading bacteria
are often able to obtain heme directly from the circulating pool of hemoproteins. Some
pathogens also deploy hemolysins to trigger erythrocyte destruction and hemoglobin
release (41, 156, 157).

Ironically, while heme is essential for many functions, the transitional nature of the
coordinated iron renders it a significant pro-oxidant that can harm many cellular entities
including DNA, proteins, cytoskeleton, and membranes (81, 158, 159). To prevent
cellular damage and to control infections, mammals restrict the pool of free circulating
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hemoproteins through scavenger proteins such as serum albumin, hemopexin (for heme),
and heptoglobin (for hemoglobin) (160, 161). To minimize oxidative damage, the cellular
levels of heme are managed by heme oxygenases. These enzymes degrade heme to
biliverdin, which is then reduced to the cytoprotectant molecule bilirubin (162). Since
heme could act as a menace, it is advantageous only in amounts that meet the bacterial
requirements and, as long as it remains sequestered, preventing access to susceptible
macromolecules (85). Bacteria that are exposed to heme and take advantage of it during
infection had to develop strategies to manage its toxic effects. While we do not fully
understand how bacteria avoid and manage the negative ramifications of heme exposure,
recent studies have begun to shed light on some of the molecular mechanisms that are
involved in this process (85, 95, 163).

Heme tolerance in bacteria is typically based on tight regulation of heme uptake and
degradation. Often bacteria employ Fur- or DtxR-like metallorepressors to orchestrate
heme metabolism in response to iron availability (41, 164). In some cases, auxiliary
defense systems that facilitate repair, detoxification, and expelling of heme surplus are
activated when the cellular mechanisms for heme homeostasis are overwhelmed. A
number of two-component systems (TCS) that coordinate the response to heme stress
have been described in bacteria. The Heme Sensor System (HssRS) is a TCS that
activates the expression of a heme efflux transporter (hrtAB) in Staphylococcus aureus,
Bacillus anthracis, and possibly the Group B Streptococcus (GBS) (95, 165, 166). In
response to heme pressure, the ChrAS TCS from Corynebacterium diphtheria inhibits the
heme biosynthetic gene, hemA, and activates the transcription of the heme oxygenase
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gene, hmuO, required for heme catabolism (167-170). Interestingly, in addition to
putative HssRS TCS, GBS also codes for pefR, a heme-responding repressor (95). PefR
binding to heme leads to derepression of two heme export systems, namely pefAB and
pefCD (95). It is suggested that GBS uses PefR to fine-tune heme homeostasis, while it
deploys the HssRS system in response to high heme exposure.

As mentioned above, bacteria often detoxify, using active export systems that directly
eliminate accumulated heme or its toxic byproducts. The efflux system, MtrCDE, in
Neisseria gonorrhea, is crucial for bacterial resistance to hydrophobic agents and heme;
overexpression of this machinery leads to increased bacterial burden in vaginal fluids
(171, 172). GBS mutants in pefAB or pefCD genes are over-sensitive to heme and
demonstrate increased accumulation of intracellular heme and PPIX (95). Respirationlinked studies in Lactococcus lactis incriminated the hrtAB homologous genes ygfAB in
heme efflux (173). A family of cytoplasmic proteins that bind and sequester heme forms
another facet of heme tolerance. The proteins HemS of Yersinia enterocolitica, ShuS of
Shigella dysenteriae, PhuS of Pseudomonas aeruginosa, and HmuS of Y. pestis are
established members of this family (87, 120, 174-177). Interestingly, the enzymes SodC
of Haemophilus ducreyi and AhpC of the GBS have both heme sequestration roles in
addition to enzymatic activity (174, 178). Bacteria also degrade heme to alleviate
toxicity. Heme oxygenases were described in several pathogenic bacteria (103, 179-181).
Despite the clear role heme metabolism has in pathogenesis, our understanding of heme
tolerance is lacking in numerous pathogens.
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The Group A Streptococcus (GAS) is a Gram-positive obligate human pathogen. GAS
infections range from mild diseases such as pharyngitis and impetigo to invasive and
systemic manifestations, including necrotizing fasciitis and streptococcal toxic shock
syndrome.

GAS

can

also

produce

post-infection

complications

such

as

glomerulonephritis and rheumatic fever (182). In the absence of a vaccine, GAS
infections are commonly treated with β-lactam antibiotics. However, due to the swift
progression rate and extent of tissue damage, surgical intervention is often required to
manage invasive GAS infections (183). The grave nature of invasive GAS infection is
attributed to many virulence factors, including its β-hemolytic property that causes
massive erythrocyte and tissue lysis (184). GAS requires iron for growth and the
pathogen can fulfill its needs for the metal by acquiring heme from lysing erythrocytes
(30, 131). Heme acquisition is mediated by the sia (streptococcal iron acquisition)
operon that facilitates heme relay and transport across the bacterial membrane (32, 132,
133, 185, 186). In vivo studies on a second operon named siu (streptococcal iron uptake)
linked it to the uptake of heme and ferric ion (30). Although heme receptors and transport
proteins have been identified, our understanding of heme metabolism in GAS is still
incomplete. The focus of this study was to fill in the knowledge gaps in GAS heme
tolerance. Here, we show that excess heme is inhibitory for the growth of GAS in vitro;
heme exposure caused a global transcriptome shift wherein it significantly up regulated
genes that are important for redox stress, which includes sensing and management along
with protein damage and rescue.
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4.2

Materials and Methods

4.2.1

Bacterial strains and growth conditions.

Strains and plasmids used in this study are listed in Table 3. GAS was grown under static
conditions at 37 °C in Todd-Hewitt broth with 0.2% (wt/vol) yeast extract (THY broth,
Difco Laboratories) or in C-medium consisting of 0.5% Proteose Peptone #3 (BD), 1.5%
yeast extract (BD), 10 mM K2HPO4, 0.4 mM MgSO4, 17 mM NaCl, adjusted to pH 7.5
(187). In some experiments, hemin chloride (Sigma) from stock solutions prepared in
DMSO was added to the growth media at different concentrations. E. coli cells were used
for cloning and protein expression purposes. E. coli was grown aerobically in a LuriaBertani medium (pH 7.0) supplemented with kanamycin (30 μg/ml) at 37 °C.

4.2.2

Determination of the minimal inhibitory concentration (MIC). Agar
dilution method

This procedure was performed as described in (188) with minor modifications. Briefly,
the turbidity of overnight grown cultures in C-media was adjusted to OD600nm = 0.08-0.1,
representing the turbidity of 0.5 MacFarland’s acidified barium chloride standard as
described (Washington, 1974) and spotted (1 μL) onto C-medium agar containing
varying concentrations of heme. The plates were incubated overnight at 37 °C and the
minimal heme concentration that did not allow for significant bacterial growth was
determined. Broth macrodilution method: this method was performed as per the
instruction of (188). In brief, THYB containing heme at a range of 0-100 μM in 5 μM
intervals was inoculated with GAS cells (OD600nm = 0.05) and incubated at 37 °C for 17
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hours. The minimal heme concentration that did not support growth (OD600nm ≤ 0.2) was
determined. Disc diffusion method: this procedure was adapted from (189). Briefly,
sterile Whatman filter paper discs (8.0 mm diameter and 1.2 mm width) were submerged
in 10 mM heme (in DMSO) and impregnated onto C-media agar that was plated with 0.1
ml of GAS culture (final OD600 nm = 0.1). The plates were incubated at 37 °C for 17 hours
and the zone of clearance around the discs were measured.

4.2.3

Thiobarbituric acid-reactive-substances (TBARS) assay for lipid damage.

GAS culture samples with equal cell numbers were harvested 30, 60, and 90 min
following treatment with 4 μM heme (in 0.035% DMSO) or with mock (0.035% DMSO,
control) and washed twice with phosphate buffer saline, pH 7.4 (PBS). The resulting cell
pellets were resuspended in 5 ml of PBS with lysozyme (1 mg/ml, Sigma) and 400 U of
mutanolysin (sigma) and incubated at 37 °C for 30 min. The cells were then subjected to
sonication (5 sec., 10% amplitude). TBARS formation in the membrane samples was
quantified using the TBARS assay kit (ZeptoMetrix Corporation) according to the
manufacture’s recommendations. Briefly, 100 μl cell lysate samples were treated with
100 μl of SDS and 2.5 ml of the TBA reagent and incubated at 95 °C for 60 min. The
sample supernatant was collected following 10 min incubation on ice by centrifugation
(15 min at 835×g). The absorbance at 532 nm (indicative of TBARS) was measured
using the DU 730 Life Science UV/Vis spectrophotometer. The amount of TBARS in the
experimental samples was derived from a standard curve generated using the
malondialdehyde (MDA) reagent supplied with the kit.
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4.2.4

Detection of protein damage.

The TBARS assay was followed as above except the cell pellets were washed twice with
TSM buffer (100 mM Tris, 500 mM sucrose, 10 mM MgCl2, pH 7.0), resuspended in 0.5
ml of TSM with 400 U of Mutanolysin (Sigma) and incubated at 37 °C for 30 min. The
protoplasts were centrifuged at 20,000×g for 5 min at 4 °C, suspended in 0.2 ml of lysis
buffer (50 mM Tris-HCl, 60 mM KCl, 10 mM MgCl2, pH 7.0, 2% β-mercaptoethanol)
and subjected to sonication (10 Sec. 10% amplitude). The membrane components were
collected by centrifuged at 100,000×g for 30 min at 4 °C. The supernatant was retained as
a cytoplasmic fraction and pellets were resuspended in 0.2 ml of lysis buffer and were
considered as the membrane fractions. Protein damage was detected using the OxyBlot™
protein oxidation detection kit (Millipore) according to the manufacturer’s instructions.
In this assay, oxidized proteins are derivatized with 2,4-dinitrophenylhydrazine (DNP),
which is then detected with primary antibodies specific for DNP and secondary antibody
conjugated to horseradish peroxidase (HRP) using a chemiluminescence protocol. The
intensity of the signal in individual lanes was quantified using ImageQuant LAS 4000
and the ImageQuant TL software (GE).

4.2.5

RNA extraction.

Cell samples were harvested 30, 60, and 90 min following heme or mock treatment by
centrifugation (5000×g for 20 min) at 4 °C. RNA was extracted from the cell pellet using
the RiboPure™ RNA purification kit (Ambion) followed by DNaseI digestion (Ambion)
performed according to manufacturer's instructions. Microarray analysis was performed
with total RNA extracted from 90 min post treatment cell samples. Real-time RT-PCR
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transcript analysis for selected genes was performed using total RNA extracted from all
three-time points post treatments.

4.2.6

Microarray analysis and Real-Time RT-PCR validation.

The GAS microarray used in this study (190) consists of 2,328 70-mer oligonucleotide
probes targeting unique non-repetitive ORFs from the sequenced genomes of serotypes
M1 (SF370), M3 (MGAS315), and M18 (MGAS8232). Probes were synthesized by
Qiagen Operon with a melting temperature of 76 ± 5 °C, ≤ 70% cross-hybridization
identity to another gene within the same strain, ≤ 20 contiguous bases in common with
another gene, and probe location within 3′ end of ORF. Microarrays were printed at
Microarrays Inc. (http://www.microarrays.com), with 10 pl of each oligonucleotide probe
spotted onto slides (UltraGAPS2; Corning) using a 12-pin contact printer. The microarray
hybridization was performed as previously described (191). Briefly, 10 μg of DNase Itreated total RNAs to be compared were used for reverse transcription into singlestranded cDNA using 200 U Superscript II reverse transcriptase (Life Technologies), 6
μg random hexamers, 1X first strand buffer, 10 mM dithiothreitol (DTT), 0.5 mM dATP,
0.5 mM dCTP, 0.5 mM dGTP, 0.3 mM dTTP and 0.2 mM of amino-allyl dUTP. The
mixture was incubated at 42 °C for 2 h and the reaction stopped by addition of 10 μl
0.5 M EDTA and 1 M NaOH. Amine-modified cDNA was purified by ethanol
precipitation followed by chemical labeling with Cy3- or Cy5-NHS-ester fluorescent
dyes (GE Healthcare) in a final step. Yield and incorporation of dye was determined
using a Nanodrop ND-1000 (Thermo Scientific). Slides were pre-hybridized in a 50 ml
solution of 5X SSC, 0.1% SDS and 1% BSA for 30 min at 42 °C, washed 4X in water
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and once in isopropanol, then dried by brief centrifugation. Labeled probes were
resuspended in hybridization buffer (30% formamide, 5X SSC, 0.1% SDS, 0.6 μg/μL
salmon sperm DNA) and hybridized to the microarray slides in a 42 °C water bath for 1620 h. Slides were washed twice in a low stringency buffer (2X SSC, 0.1% SDS) at 55 °C
for 5 min, twice in a medium stringency buffer (0.1X SSC, 0.1% SDS) at room
temperature for 5 min and finally twice in a high stringency buffer (0.1X SSC) at room
temperature for 5 min, and then dried by brief centrifugation. Synthesized cDNA from
each RNA sample from three independent cell cultures was hybridized on three separate
microarray slides (biological replicates), and independently synthesized cDNA from each
of these same RNA samples was hybridized in a repeat dye-swap experiment (technical
replicates) to test technical reproducibility. Slides were scanned using an Axon 4100A
personal array scanner and GenePixPro 6.0 software (Molecular Devices). Data obtained
from MGAS5005 cells incubated in the presence of DMSO or 4 µM of heme were
compared for twofold changes in expression, ≥ 2.0 or ≤ 0.50 with Acuity 4.0 software
(Molecular Devices). Using a ratio-based normalization, data were normalized by the
ratio of the means (635/532) and samples were removed when four out of the six
experiments did not show significance. Data was validated on 11 independent genes by
real-time RT-PCR as described below.

Correlation coefficients for the arrays were

determined by plotting the log value of the array on the x-axis to the log value of the realtime RT-PCR on the y-axis. An equation determining the line of best fit was determined,
and the resulting R2 value was calculated to be 0.889. Array data was submitted to the
Gene Expression Omnibus (GEO) at the National Center for Biotechnology Information
under the accession number GSE61415.

47

4.2.7

Quantification of expression by real-time RT-PCR.

For microarray data validation, real-time RT-PCR analysis was carried out using primers
in Table 4 as follows: 25 ng of DNaseI-treated total RNAs were added to SYBR green
master mix (AB) containing 5 µg of each specific real-time primer for the one-step
protocol. The real-time RT-PCR experiments were completed using a LightCycler 480
instrument (Roche), and levels represent the ratio of non-treated to treated experimental
values relative to the level of expression of gyrA transcript as an endogenous control. For
expression of the pefRC operon, a SYBR Green based quantitative PCR reactions were
performed using the Power SYBR® Green RNA-to-Ct™ 1-Step Kit (AB) on 7500 Fast
Real-Time PCR machine (AB) according to the manufacturer’s specifications. Briefly,
the reaction mixture (20 µl) contained, 10 µl of RT-PCR Mix (final 1X), 10 nM of each
forward and reverse primers, 25 ng of total RNA, and RT enzyme Mix in 1X final
concentrations. The relative quantification with comparative ΔΔCT method was
employed to calculate differences in pefRC expression levels at different times after heme
exposure. The relative expression levels of pefR and pefC genes were normalized to the
level of rpsL transcript as an endogenous control. The levels of transcripts in heme
treated samples were compared to the control samples.

4.2.8

In silico analysis.

The PefR binding motif was identified within the putative promoter region of
MGAS5005 spy_0195 (pefR) using Multiple Em for Motif Elicitation (MEME) suit
hosted by the National Biomedical Computation Resource (192). The outcome was
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further analyzed by the MAST application of MEME for its genome wide occurrence
within the upstream sequences of GAS under both the stringent (E value ≤ 0.01) and
relaxed (E value ≤ 10) parameters. All of the sequences were acquired from Kyoto
Encyclopedia of Genes and Genomes (KEGG) database (193) for comparative sequence
analysis; sequences were aligned using ClustalW (194).

4.2.9

Cloning, overexpression, and purification of PefR.

The spy_0195 ORF was amplified from GAS MGAS5005 genomic DNA by PCR using
primers ZE515 and ZE516 (Table 4). To generate pAJS11 plasmid (Table 3), the PCR
fragment with pefR ORF was cloned into the pRham™ expression vector (Lucigen) by
Expressioneering™ technology and introduced into E. cloni® 10G competent cells. The
cloning was confirmed by sequence analysis. For PefR expression, cells harboring
pAJS11 were induced at OD600nm = 0.8 with 0.2% rhamnose. The cells were harvested
(8,000×g for 5 min at 4 °C) following 16 hours incubation at 28°C. The resulting pellets
were resuspended in extraction buffer (20 mM Tris pH 8, 100 mM NaCl, 0.1% Triton X100) containing 0.5 mg/mL Complete, mini-EDTA-free protease inhibitor cocktail
(Roche), sonicated and the cell debris were removed by centrifugation. The resulting
lysate was purified over 5 ml HisTrap™ HP (GE) nickel affinity column. Protein
fractions were dialyzed overnight in sodium phosphate buffer (SPB: 20 mM sodium
phosphate, 500 mM NaCl pH 7.4). Expression of the recombinant PefR was evaluated by
SDS-PAGE and western blot analysis with mouse anti-His antibodies (Sigma).

4.2.10 Heme and PPIX binding assay.
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Heme binding by PefR was assessed spectroscopically as described in (125, 185) with
minor modifications. Briefly, an increasing concentration of hemin chloride (2-30 μM)
was added to both the test cuvette containing 10 μM of PefR protein in SPB and the
reference cuvette (containing SPB alone) and the changes in absorbance across the
wavelength of 250 – 700 nm region were recorded every 6 min. The PefR to heme
stoichiometry and dissociation constant (Kd) were determined by plotting the absorbance
at 435 nm as a function of the heme concentrations. The extinction coefficient (εmax) for
PefR was calculated from the hemocromogen method described in (195). All of the
spectroscopic measurements were made using the DU730 Life Science UV/Vis
spectrophotometer (Beckman Coulter). PPIX binding was tested by titrating PefR (5 μM)
with

0-6

μM

PPIX

(in

0.5

μM

increments)

prepared

in

acidified

methanol:dimethylformamide (1:1). The changes in absorbance were recorded.

4.3

Results

4.3.1

Excess of heme is inhibitory to the growth of GAS.

Host heme is the immediate source of iron during infection for invading pathogens such
as GAS. Recent studies demonstrated that bacteria must maintain the intracellular levels
of heme at equilibrium in order to benefit from its nutritional value, while eluding the
toxicity that is associated with heme overload (95, 166, 196). In this work, we began
evaluating the impact of heme on GAS physiology. We found that the addition of a disc
saturated with 10 mM heme onto agar plates seeded with a confluent lawn of GAS
resulted in a zone of clearance similar to those observed with antibiotic-impregnate discs.
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This observation indicates that heme can have a bacteriostatic effect on GAS (Table 5).
To compare the sensitivity to heme among GAS isolates we determined the MIC values
of heme using two common methods (Table 5). The agar dilution assay employs solid Cmedium containing varying concentrations of heme. We determined that the heme MIC
in this method is between 10 to 20 μM with the nephritogenic M49 GAS skin isolate,
NZ131 (197, 198), exhibiting the highest sensitivity of all GAS strains tested. The highly
pathogenic M1T1 MGAS5005 strain (199) as well as clinical isolates from patients with
invasive diseases (Table 3) demonstrated higher heme tolerance. In the broth dilution
assay, we measured bacterial growth in THYB supplemented with varying heme
concentrations. This method resulted in higher values of heme MIC (30-50 μM) for
MGAS5005 and the clinical isolates. However, both methods indicated that the invasive
strains were more resistant to heme than NZ131.

4.3.2

Exposure to sub-lethal heme levels cause lipid peroxidation in GAS.

To learn why heme is detrimental for GAS growth, we investigated its impact on GAS
macromolecules. Heme is reported to damage directly or through the generation of
reactive oxidative species the integrity of membrane lipids (81, 200). Therefore, we
evaluated the extent of lipid peroxidation in GAS following heme exposure. Using low
heme concentration that could still support cell growth when applied at the early
logarithmic phase allowed us to examine the kinetics of damage production and later the
bacterial transcriptome response to heme. As seen in Figure 13A, the addition of 4 μM
heme to MGAS5005 at the early logarithmic phase of growth did not result in a
significant change in the bacterial growth profile. To detect lipid peroxidation, we used
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an established method that relies on the tendency of oxidized lipids to react with a
thiobarbituric acid (TBA) reagent to form adducts (named TBARS) that absorb at 532 nm
(201). The time course of TBARS production in GAS cells exposed to heme (or in
control samples) was quantified using a standard curve (Figure 13B). Significantly higher
occurrence of lipid peroxidation was observed in all of the heme-treated samples
compared with control samples (Figure 13C). Lipid peroxidation was the highest (22.5
fold over background) 30 min after heme treatment; while lower levels (~5 fold over
background) were found in the samples collected 60 and 90 min post-heme treatment
(Figure 13C), indicating possible repair mechanism. In eukaryotes, membrane repair
involves enzymes such as phospholipase A2 that hydrolyse peroxidized fatty acid esters
and glutathione peroxidase (202, 203).

4.3.3

Exposure to heme damaged membrane proteins.

We next evaluated the effect of heme on GAS proteins. Oxidation introduces carbonyl
groups into protein side chains that can then react with 2,4-dinitrophenylhydrazine
(DNPH) to generate 2,4-dinitrophenylhydrazone (DNP) derivatives (204). To monitor
protein oxidation in GAS, membrane and cytoplasmic proteins were extracted from
culture samples collected at 30, 60, and 90 min post treatment and allowed to react with
DNPH. Oxidation was then visualized by immunoblot with antibodies specific for DNP
and the damage was quantified by densitometry. Analysis of the membrane fractions
revealed that the anti-DNP antibody strongly reacted with all of the samples from heme
exposed cells (Figure 14A, upper panel). While general staining confirmed the presence
of proteins in all samples (Figure 14A, bottom panel), protein oxidation was only
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observed in the heme-treated cells in the early sample. At the later time points (60 and 90
min) some background oxidation also occurred in the control samples. In all cases
though, a significantly higher amount of protein damage was observed in the hemeexposed cells compared to the controls (Figure 14C). In addition, the degree of protein
oxidation was the highest in the 90 min samples. Similar analysis of cytoplasmic proteins
did not reveal detectable damage (Figure 14B); therefore, protein oxidation following
heme exposure is primarily linked to the membrane fraction under our experimental
conditions.

4.3.4

GAS demonstrates adaptation response to heme.

When overnight cultures of NZ131 grown in heme-free medium were inoculated into
medium containing 1

M heme, which is below the growth inhibiting concentrations at

the early logarithmic phase, an extended lag phase that lasted for more than 8 hours was
observed (Figure 15). Although exposure to heme inhibited growth initially, the cultures
reached after overnight incubation the cell density observed in cultures that grew in
heme-free medium (data not shown). To test for possible adaptation to environmental
heme, GAS cells were grown overnight in the presence of 0.1 M heme before they were
inoculated into medium with 1

M heme. Indeed, pre-exposure to low heme level

eliminated the extended lag period (Figure 15). These observations suggest that the
treatment with low level of heme-triggered adaptation to environmental heme.

In light of recent evidence that bacteria can sense and respond to heme (95, 163, 196,
205) and with evidence for a similar response in GAS, we wanted to gain insight into the
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pathogen’s mechanisms for heme sensing and tolerance. We examined the differential
global gene expression pattern between GAS cells subjected to heme stress (4 μM) and
control treatment. Total RNA was isolated from cells 90 min post treatment and analyzed
using a 70-mer oligonucleotide microarray (representing GAS genomes M1, M3 and
M18) (190). Our data showed a significant shift in the transcript profile of different genes
and operons in response to heme stimulus; referred to as the ‘GAS heme stimulon’. This
stimulon involved changes in 163 total genes, including 79 genes that were up regulated
and 84 genes that were down regulated (Figure 16 and Supplementary Table 1). The
array analysis was validated by quantitative RT-PCR (qPCR) on 11 differentially
regulated genes (Supplementary Table 1), showing a strong correlation, with an R2 value
of 0.889 (Supplementary Figure 1).

Genes that were down regulated significantly in response to heme are found in the
categories of metabolic pathways, sugar and metabolite transport, and two-component
system (TCS, Figure 16A). Of particular interest is the down regulation of the TCS,
trxSR. The response regulator, TrxR activates the Mga virulence regulon in GAS, and a
trxR mutant is attenuated for virulence in a murine infection model (206, 207). Therefore,
environmental heme may impact the expression of key virulence factors in GAS via the
TrxSR/Mga pathway. Since the TrxSR system is implicated in asparagine sensing, our
observations also imply that the damage to the cell envelope introduced by heme is
associated with increased levels of asparagine (or other amino acids) (206, 207). In
contrast, heme-activated genes and highly expressed transcripts encode for protein
folding and degradation (such as groEL/ES ~8 fold, DnaJ/K 3-4 fold, and clpE/L ~4 fold)
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and components of the Clp protease machinery (clpCP- 2.5 fold) (208, 209) (Figure
16B). In addition, the GAS heme-activated stimulon includes genes whose functions are
linked to regulation of redox stress management, including spx (5 fold) and ctsR (2.5
fold) (210, 211). Accordingly, members of the downstream genes of these regulators
were also activated by heme such as thioredoxin (trx ~2.5 fold) and oxidoreductases (3
fold). Finally, the expression of two TCSs was also up regulated in response to heme
exposure, including the pneumococcal-like TCS homologous system, ciaHR (~2.3 fold)
(212) and the ihk/irr TCS (2.5 fold) involved in GAS response to oxidative stress and
survival within phagocytes (213).

4.3.5

Identification of the pefRCD locus in GAS.

The transcriptomic analysis also revealed that several putative efflux proteins also
showed an increase in transcriptional activity in response to heme stress. These included
a 3-gene cluster (MGAS5005 spy_0195, 0196, and 0197) with homology to the pefRCD
genes from GBS (95). Since the pefRCD genes are important for the management of
heme stress in GBS, we focused our attention on their heme-induced homologs in GAS.
Comparative sequence analysis demonstrated that the putative GAS genes, spy_0195
(84% similarity; 56% identity), spy_0196 (76% similarity; 48% identity), and spy_0197
(76% similarity; 51.3% identity) show significant sequence homology to the GBS
pefRCD genes, respectively (Figure 17). In addition to the high sequence homology
demonstrated by each of these GAS genes, the genomic arrangement of the GBS pefRCD
locus and its immediate chromosomal location are also conserved in all of the published
GAS genomes (Figure 18A). Moreover, using the MEME algorithm, we identified a 17-
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bp inverted repeat region within the putative promoter of spy_0195 that shared 76%
identity with the PefR binding site from GBS (Figure 18A). Based on this sequence
conservation and the observed induction by heme, we hypothesized that like GBS, the
above-mentioned GAS genes encode a heme dependent repressor (spy_0195) and an
ABC heme exporter (spy_0196 and spy_0197) and named them pefRCD, respectively.

We examined the time course of pefRC expression in response to heme by qPCR (Figure
18B). As seen in the microarray analysis, the expression of pefR and C was comparable
to one another in all of the time points, supporting an operon structure. Heme exposure
resulted in an increase of pefR and pefC expression over time, reaching 2.5 fold over
background at 30 min, 4.5 fold at 60 min and remained high at 90 min post treatment.
This temporal increase in pef expression in response to heme insinuates an active
participation of these genes in heme tolerance.

4.3.6

GAS PefR binds heme and PPIX with high affinity.

In GBS, PefR is a MarR-like repressor that binds to DNA and blocks the transcription of
both pefRCD and pefAB operons. In this system, heme acts as an inducer that binds to
PefR protein to alleviate repression. The GAS protein shares 43% identity and 74%
similarity with PefR from GBS (Figure 17), implying the two proteins may function in a
similar manner. We cloned the pefR gene from GAS and expressed it as an N-terminal
hexahistidine (6x-His) fusion protein. SDS-PAGE and western blot analysis of the
recombinant protein following purification from E. coli confirmed the presence of a
single protein at the expected size that reacts with anti-his tag antibodies (Figure 19A and
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data not shown). Interestingly, the purified PefR had a light brown color (Figure 19B, left
inset) and exhibited an absorption in the Soret region (435 nm). Upon titration with free
heme, PefR displayed a growing Soret band and concomitant increase in absorption at
530 and 560 nm (β and α bands of heme). These spectral features are characteristics of
heme bound protein and are easily separated from the absorption displayed by heme that
is free in solution (214). The holo-PefR maintained a bright red color after the removal of
heme excess by gel filtration and dialysis (Figure 19B, right inset). Therefore, PefR was
purified from E. coli with some heme and readily bound heme in vitro. The plot of
changes in absorbance at 435 nm as a function of heme concentrations indicated a
binding stoichiometry of 1:2 (PefR:heme, Figure 19C). We determined the dissociation
constant (Kd) for PefR by fitting the plot of changes at 435 nm in the modified Hill’s
equation (215). We found the Kd to be 10 μM and Hill’s coefficient (nH) to be 1.3,
greater than 1 (216). The molar extinction co-efficient at 435 nm of holo-PefR was
determined using the pyridine hemocromogen method (195) and resulted in ε435 = 30,407
M-1cm-1. Similarly, titration of PefR with PPIX indicated that it could also bind PPIX in
1:1 stoichiometry with Kd of 9 μM (Figure 20).

4.4

Discussion

It is the biochemical properties of heme that contribute to its characteristics as a doubleedged sword in a variety of biological systems. Heme toxicity in humans stems from the
lysis of erythrocytes due to disease, inflammation, or physical damage, which could raise
the heme levels in the bloodstream up to 20 μM (217, 218). The generation of reactive
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oxygen species, alteration in membrane permeability, damage to macromolecules, and
decrease in the pool of reductants are some of the cellular mayhem that follows heme
overload in eukaryotes (218). In bacteria, despite the importance of heme to physiology
and pathogenesis, the molecular mechanisms for heme toxicity and tolerance are poorly
understood (85). In this study, we probed these processes in GAS for the first time and
established that heme stress is very significant to the physiology of the

-hemolytic

pathogen; heme in excess inhibits GAS growth and exposure to low heme levels damages
membrane lipids and proteins. We demonstrated the presence of an adaptation process to
environmental heme in GAS and revealed a comprehensive transcriptome response to
excess heme exposure. Finally, our findings also implicate a new gene cluster, pefRCD,
in GAS heme sensing and tolerance.

We found that heme tolerance in GAS depends on medium type, growth conditions and
genetic background (Table 5). Differences in bacterial metabolism, aeration, and cell-tocell contact may all affect the bacterial sensitivity to heme. In addition, the THY medium
is prepared from brain and heart infusion and is likely to contain some heme. Growth in
THYB therefore, may allow for bacterial adaptation, possibly contributing to the higher
heme MIC values observed in this medium. A significant variation in heme tolerance was
exhibited by different strains of GAS; with NZ131, a serotype M49 skin isolate (197,
198), demonstrating the lowest heme tolerance, whereas the more invasive strains such as
M1T1 MGAS5005 (199) and other clinical isolates showing higher heme resistance. It is
tempting to speculate that these variations in heme sensitivity might add to the inclination
of different GAS strains to colonize certain sites and to their invasive potential.
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The absence of significant damage to cytosolic proteins in GAS suggests that the
membrane is the primary target of heme in this bacterium (Figures 13 and 14). This
observation is in accordance with findings made in S. aureus (219) and is likely to result
from heme accumulation in the cell envelope. The negative regulation of the heme uptake
machinery works to limit the amount of heme that can reach the GAS cytoplasm (30, 32,
220). In addition to active import, heme can diffuse through biological membranes, albeit
with slow diffusion rates that can lead to accumulation in this compartment. Indeed it is
well established that heme surplus tends to accumulate in the membranes of the
eukaryotic cells, where it can be transformed into highly reactive species (81, 161). There
is less information regarding heme localization in bacteria; however, studies in S. aureus
suggest a similar buildup in the cell envelope (221). In addition to the preferential
localization of heme outside of the cytoplasm, the reducing environment and the detox
mechanism induced by heme (e.g. heat shock and redox factors) could mitigate some of
the oxidative effects of the heme in this compartment. In this study we only probed the
impact of heme at 4 M, a concentration that is below the MIC level in early exponential
phase, and for 90 min post treatment. Further investigations are needed to determine if
heme at higher concentrations or after longer exposure time is affecting other cellular
compartments.

The extended lag period that is observed when naïve GAS cells are introduced into
medium containing heme and the absence of the growth delay in cells that were preexposed to low heme levels (Figure 15) provide strong evidence for the presence of heme
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sensing and coping mechanisms in GAS. Indeed, microarray analysis indicated that heme
triggers comprehensive changes in GAS transcript levels (Supplementary Table 1 and
Figure 16A). The shift in the expression of regulatory proteins such as spx, ihk/irr, ctsR,
and hrcA and their downstream-regulated genes, suggests that heme leads to significant
redox, oxidative, and protein damage (Figure 16B). Spx is an RNA polymerase binding
protein with CXXC redox-sensing center that acts to restore thiol balance by controlling
redox enzymes and antioxidants formation (222). The ihk/irr TCS regulates oxidative
stress genes that protect GAS from killing by phagocytic cells and hydrogen peroxide
(213, 223). The induction of this regulatory system is consistent with ROS formation and
cell envelope damage following heme exposure. The master regulators CtsR and HrcA,
originally classified as class III and class I heat shock gene regulators, respectively, have
been associated with a wide variety of stresses such as temperature shifts, antibiotics,
carbonyl, electrophiles, etc. (224, 225). Here we show their association with heme stress
and the elevated expression of chaperones and clp proteases further corroborates our
hypothesis of heme-induced protein unfolding and findings of protein oxidation.

Heme treatment also resulted in significant inhibition of the genes encoding lactate
oxidase (lctO) and of a V-type ATP synthases system (ntpKCFABD). LctO reaction leads
to hydrogen peroxide production that can exacerbate the damage induced by heme (226,
227). The down regulation of the proton pump may serve to increase the reducing power
at the cell surface. Further selective down regulation of genes such as citDEFX and upregulation of fruRBA, which are involved in import and utilization of citrate and fructose,
respectively, could indicate a metabolic state that is more conducive to detoxification.
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Le Breton et al. recently used a mariner-based transposon library to screen for genes that
are important for GAS survival in human blood (228). Comparing the heme stimulon
identified in this study to the findings of Le Breton et al. revealed significant overlap,
including clpE and L, fhs.2, fruA, citF, trxS, lacZ, and the has operon. This comparison
suggests that heme, directly or indirectly, act as a signal that mediates adaptation in vivo
and that the management of heme toxicity is relevant to GAS pathogenesis, in particular
during spread through the blood.

The heme stimulon in GAS also includes three genes (spy_0195-7) that share high
homology to the GBS pefRCD genes. In GBS these genes code for a heme responsive
repressor (PefR) from the MarR-like family (229) and to an ABC heme exporter (PefCD)
(95). While the presence and genomic arrangements of pefRCD are highly conserved
among different GAS strains (Figure 17 and 18), we failed to identify homologues to
pefAB (and hrtAB) that also participate in heme tolerance in GBS and other Grampositive bacteria. The high degree of sequence similarity and the temporal increase in
expression in response to heme stress (Figure 18B) suggest that the 3-gene locus encodes
for a true homologue of the pef operon. This hypothesis is further supported by the
identification of a putative PefR heme-binding box that is highly comparable to that of
PefR from GBS (Figure 18A) (95) and by our heme and PPIX reconstitution experiments
(Figures 19 and 20). The ability of PefR to coordinate two heme molecules and curve
fitting data demonstrating positive Hill’s coefficient of cooperativity most likely suggest
that the binding of heme at one binding site increases the affinity of heme binding at
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another site (215, 216). Further experiments are underway to determine if and how heme
and PPIX are modulating PefR binding to DNA and to establish the role of this 3-gene
cluster in heme and protoporphyrin tolerance in GAS.

To the best of our knowledge our work is 1) the first effort to characterize GAS
mechanisms for heme toxicity and tolerance; 2) shows that environmental heme
constitutes a significant redox stress in GAS with damaging effects on membrane lipids
and proteins; 3) provides evidence for heme sensing and adaptation that involves global
transcriptome shifts; and 4) links heme stress to several key regulators and TCS systems
of this important human pathogen.
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5

CHAPTER 4 - THE PEFCD IS A MDR SYSTEM THAT EXPORTS HEME
AND CONFERS RESISTANCE TO HEME AND DOXORUBICIN IN GAS

5.1

Introduction

Streptococcus pyogenes or Group A Streptococcus (GAS) is a Gram positive, βhemolytic, human pathogen transmitted via respiratory droplets and direct contact. GAS
is responsible for a diverse spectrum of diseases ranging from superficial (e.g.,
pharyngitis, impetigo and pyoderma) to severe invasive infections and systemic
manifestations (such as necrotizing fasciitis and streptococcal toxic shock syndrome). In
addition, simple GAS infections can trigger autoimmune reactions in some patients
leading to neurological disorders, glomerulonephritis, or acute rheumatic fever (3, 4).
GAS encodes a large collection of virulence factors, which act to promote infections and
pathologies by various means such as bacterial adherence and invasion, evasion of the
host immune surveillance and nutrient acquisition (230). Due to the high morbidity
associated with GAS related illnesses, this pathogen is ranked 9th among the world’s
leading infectious agents (231). Recent global estimates suggest that every year about
600 million GAS infections occur, accounting for ~ 600,000 deaths (232). The reported
increase in antibiotic resistance, emergence of new strains, and absence of vaccine
programs suggest that the disease burden inflicted by GAS is likely to rise (6, 233).

GAS requires iron for growth and can retrieve the metal from heme (131). The cytolysins
produced by GAS provide the pathogen with access to the host intracellular pool of
hemoproteins. GAS proceeds with heme uptake using the streptococcal iron acquisition
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(sia) operon: heme is extracted and captured on the bacterial surface by the streptococcal
hemoproteins receptor (Shr), relayed to the streptococcal hemoprotein (Shp), and
subsequently to the substrate binding protein, SiaA (HtsA). The SiaBC importer then
internalizes the heme (32, 133-135, 186). Although heme is nutritionally beneficial, its
pro-oxidant nature renders it hazardous in surplus quantities (85). We recently observed
that exposure to sub-lethal heme concentrations elicits a global stress response in GAS
(50). This observation underscores the harmful potential of heme. Heme toxicity seems
particularly relevant to the patho-physiology of the -hemolytic pathogen, and could
impose as a significant challenge for GAS growth during invasive infections.

Heme-mediated cell injuries are primarily accredited to the coordinated iron element. The
dynamic existence of iron in two redox and spin states within heme allows it to react with
multiple biological entities including proteins, nucleic acids and lipids. This effect is
exacerbated by the participation of iron in Fenton reactions, which lead to generation of
radicals or reactive oxygen species (234). In addition to iron toxicity, the lipophilic nature
of the protoporphyrin-ring (PPIX) is associated with photosensitivity and insertion of
heme into membranes. This process was shown to undermine membrane permeability
and further potentiates the release of free-heme from erythrocytes (235, 236). In
mammalians, increased and persistent flux of free-heme in the vascular system is
associated with significant inflammation and pathology (237).

To manage heme toxicity, bacteria carefully control heme uptake according to cellular
demands. In GAS for example, a metalloregulatory protein named MtsR, directly
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represses the expression of the sia operon in the presence of iron (65). In addition to
limiting heme uptake, bacteria employ various sequestration, degradation, and active
efflux mechanisms. The export of heme excess and its role in protection against toxicity
has been increasingly recognized in bacteria. The multiple-transferable-resistance
(MtrCDE) efflux system from Neisseria gonorrhea which, expels hydrophobic
antibacterial agents (238), also facilitate resistance to PPIX, heme, and other porphyrinbased compounds. Inactivation of the mtrCDE pump resulted in increased gonococci
sensitivity to porphyrins and metalloporphyrins, while overexpression of this system
endowed cells with an increased tolerance to porphyrin based compounds (239). The E.
coli MacAB pump is another example of an active exporter with broad specificity that
contributes to heme tolerance. MacAB (with the TolC outer membrane channel protein)
enables eneterotoxin secretion and confers resistance to macrolides (240, 241). In
addition, MacAB-TolC serves as the major PPIX exporter in E. coli (242).

In Gram-positive organisms, the archetype of an exporter that mediates heme tolerance in
several bacteria including Bacillus anthracis and Lactococcus lactis was identified first in
Staphylococcus aureus and named heme-regulated transporter (HrtAB) (94, 96, 243,
244). Work performed in L. lactis suggested that this system exports heme directly from
the membrane, acting to limit heme accumulation in this compartment (96, 245). The
expression of the hrtAB genes is tightly regulated according to heme availability via the
two-component system HssRS (in S. aureus and B. anthracis) or the heme-dependent
repressor, HrtR (L. lactis) (94, 96, 246). The presence of the HrtAB transporter and the
associated regulatory network bestows bacteria with elevated heme sensing and
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resistance capacity. Studies in mouse infection model demonstrated that the HrtAB
promoter in B. anthracis is induced in vivo, suggesting that the HrtAB transporter is
recruited during infection, presumably to alleviate heme toxicity (94). Interestingly, while
both species exhibit similar sensitivity to environmental heme, the loss of hrtA in B.
anthracis has a more pronounced impact than in S. aureus, implying that heme sensing
and/or detoxification by the HssRS and HrtAB systems are more effective in B. anthracis
than in S. aureus. (94). The genome of Group B streptococcus (GBS) contains putative
hrtAB homologs that are regulated by heme availability. However, contribution of these
genes to heme efflux and tolerance in GBS has yet to be determined. In addition, GBS
carries a regulon called porphyrin regulated efflux (pef) whose expression is controlled
by PefR, a MarR-like repressor (95). Heme or PPIX allow for transcriptional activation
of the pef regulon by relieving PefR binding to its operator. The pef regulon consists of at
least two separate gene clusters (pefAB and peRCD) that encode two distinct transporters,
pefAB and pefCD. Inactivation of the GBS pef transport system results in increased
sensitivity to heme and intracellular buildup of heme and PPIX. Overexpression of these
systems led to heme depletion and a defect in both respiratory metabolism and virulence
(95). In Listeria monocytogenes, an ATP-dependent transporter, FrvA (Fur regulated
virulence factor A), was implicated in heme export and protection from heme toxicity
(247). Notably, the FrvA transporter is essential for the systemic infections in mice
models.

Mechanisms of heme tolerance are poorly understood in GAS. We recently identified a
three-gene operon in GAS that shares significant similarity to the GBS pefRCD genes.
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We demonstrated that these genes are up regulated in response to heme exposure and
implicated the PefR homolog in heme sensing and regulation of the gene cluster (50). In
this study, we set to determine the function of the pefCD genes in GAS physiology.

5.2

Materials And Methods

5.2.1

Bacterial strains and growth conditions

Plasmids and strains used in this study are listed in Table 6 and the primers are described
in Table 7. E. coli cells were used for cloning and propagation of plasmids. E. coli was
grown aerobically in Luria-Bertani medium (BD) at 37 °C (pH 7.0 ). GAS was grown
under static conditions in Falcon tubes or nephelometer flasks in THYB: Todd-Hewitt
broth (TH broth, Difco laboratories) with 0.2% (weight/volume) yeast extract (BD).
Growth was measured using a Klett-Summerson colorimeter (A filter) and / or by viable
counting. In some cases, hemin chloride (Sigma) prepared in DMSO (0.035% final
concentration, Fisher BioReagents) was added to the cultures. Antibiotics were used at
the following concentrations: Spectinomycin at 100 g/ml for both E. coli and GAS, and
kanamycin at 70 g/ml for E. coli and 300 g/ml for GAS.

5.2.2

Nucleic acid methods.

Chromosomal and plasmid DNA extraction and DNA manipulations including restriction
digests, cloning, and DNA transformation were done according to the manufacturer’s
recommendations and with standard protocols as previously described (248). Plasmid
DNA was isolated from E. coli using the Wizard Plus SV mini-prep system (Promega).
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DNA was subjected to restriction digestion (SpeI-HF® and or EcoRI of NEBL), and
fragments were gel purified from agarose using S.N.A.P. UV-free gel purification kit
(Invitrogen). The digested and gel purified fragments were ligated using T4 DNA ligase
(Roche) to generate a recombinant construct.

5.2.3

Construction of plasmids, GAS mutants and complementation strains:

The pefC::pMZ1 mutant, ZE4951, was constructed in NZ131 background by Campbell
insertion using plasmid pMZ1. Briefly, an internal 696 bp fragment from the pefC gene
was amplified from NZ131 chromosome using ZE565 and ZE566 primers and ligated
into the EcoRI site in pUC-Spec, which carries the spectinomycin resistance gene, aad9
(249). The resulting plasmid, pMZ1, was introduced into NZ131 strain and
spectinomycin resistant colonies were selected. The structure of the chromosomal
pefC::pMZ1 mutation was verified by PCR and sequence analysis. For complementation
analysis, a 4336 bp fragment spanning the pefRCD operon including the promoter region
was amplified from NZ131 chromosome with ZE634 and ZE635 primers and ligated into
the SpeI site of the shuttle vector, pKSM201 (250), which carries the kanamycin
resistance gene aphA3, generating pANKITA5b. The plasmids pKSM201 (empty vector)
and pANKITA5b were introduced into ZEM4951 strain by selection for spectinomycin
and kanamycin resistance.

5.2.4

Heme and doxorubicin sensitivity assay

GAS sensitivity was tested using the Disc Diffusion method as previously described (50).
Briefly, sterile 8.0 mm Whatman filter paper discs (with 1.2 mm width) were submerged
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in 10 mM heme or 1.6 mM Doxorubicin (prepared in water) solutions, dried and
impregnated onto THYA that was plated with 0.1 ml (OD600nm = 0.1) of overnight GAS
culture. The plates were incubated at 37°C for 17 hours before the zone of clearance
around the discs was measured.

5.2.5

Determination of lipid peroxidation using TBARS assay

Fresh THYB was inoculated with GAS cells collected from plates: the inocula consisted
of cells grown overnight at 37°C on THYA and suspended in saline. Bacterial
suspensions at OD600 = 0.5 were diluted 1:100 into fresh THYB, incubated at 37°C, and
growth was monitored. Heme (1 μM) was added at the logarithmic phase of growth (~
60-70 Klett units) and samples (standardized according to cell density) were harvested by
centrifugation (5000×g, 20 min at 4°C) at 30, 60, and 90 minutes post exposure. The cell
pellets were washed and samples were prepared and analyzed for lipid peroxidation using
OXI-TEK TBARS (Thiobarbituric Acid Reactive Substances) assay kit (ZeptoMatrix
Corporation) as previously described (50). Sample absorbance at 532 nm was recorded
using the DU 730 Life Science UV/vis spectrophotometer. The A532 nm obtained for the
experimental samples were compared to a standard curve generated using the
malondialdehyde (MDA) reagent supplied with the kit.

5.2.6

DNA damage detection

Fresh THYB medium was inoculated with GAS cells collected from THYA plates as
described above. The cultures were treated with 5 μM heme at the logarithmic phase of
growth (~ 60-70 Klett units) and samples (standardized according to cell density) were
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harvested at 0, 30 and 90 minutes post exposure. Genomic DNA was extracted from the
cell pellet using the ArchivePure DNA extraction kit (5 PRIME). DNA purity and
concentration were determined and 0.5 μg of DNA samples were used to quantify the
formation of apurinic/apyrimidinic (AP) sites using the DNA damage detection kit
(PromoKine) per the manufacture instructions. Briefly, DNA (500 ng) was incubated
with aldehyde reactive probe containing biotin tag (ARP) solution for 1 hour at 37 °C.
Glycogen and TE buffer were added to the solution, the DNA was allowed to precipitate
at -20°C for 10 min and then collected by centrifugation at 13,000 rpm for 10 minutes at
4°C. The pellet of the biotin-tagged DNA was washed with 70% ethanol, air-dried,
resuspended in 1ml of TE buffer. The DNA samples (60 l) were added to 96 well
ELISA plate and incubated overnight at room temperature with DNA binding solution.
The signal was developed after incubation with horseradish peroxidase (HRP)streptavidin solution and developer. The signal intensity was quantified spectroscopically
at 650 nm. A standard plot depicting the absorbance at 650 nm as a function of the
number of standard AP sites of standard solution (0, 8, 16, 24, 32, and 40 ARP sites/105
bp solution) was used to determine the number of AP sites /105 bp DNA fragment in
experimental samples. As a positive control for AP site formation in GAS cells, we used
cells exposed to 10 mM H2O2 solution for 1 hour at 37°C followed by genomic DNA
extraction, labeling, and detection similar to standards and experimental samples (data
not shown).
5.2.7

Determination of intracellular hemin content

Fresh THYB medium was inoculated with GAS cells collected from plates as described
above. The cultures were treated with 3 μM heme at the logarithmic phase of growth (60-
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70 Klett units) and samples (standardized according to cell density) were collected 90
minutes post exposure by centrifugation (8000×g for 20 min at 4 °C). The cell pellet was
washed 5 times (10 ml phosphate buffered saline, pH 7.0 each), resuspended in 2 ml of
DMSO, and subjected to sonication (20 % amplitude for 30 sec.). Heme content in the
cell lysate was determined using the procedure described by Lombardo et al with small
modifications (251). Briefly, 4 ml of experimental samples along with hemin standard
solutions (0-5 μM, in DMSO) were subjected to acidified chloroform extraction as
follows: addition of 2 ml of 50 mM glycine buffer, pH 2.0 then 0.1 ml of 4N HCl (pH
2.0), 0.2 ml of 5M NaCl (pH 2.0) and chloroform (2 ml) followed by vigorous mixing for
10sec (6 times). The reactions were incubated at room temperature for 1 minute and the
absorbance by the organic phase was then determined. The absorbance at 388, 450 and
330 nm were recorded and fed into the correction equation Ac = 2×A388−(A450+A330). The
plot of Ac corrected for standard heme concentrations was used to extrapolate the hemin
concentration in experimental samples.

5.3

Results

5.3.1

The pefCD genes encode a conserved Class-1 ABC exporter

We recently reported the transcriptional activation of a 3-gene cluster (MGAS5005
spy_0195, 0196, and 0197) ensuing GAS exposure to environmental heme. We named
these GAS genes as pefRCD based on similarity in genetic organization, primary
sequence, and regulation to the previously described pefRCD operon in GBS (50, 95)
(Figure 21A). Here, our analysis showed that the pefRCD genes are highly conserved
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among GAS strains exhibiting 100% identity for PefR, 98% identity for PefC, and 99%
identity for PefD protein (for all 20 strains in the database). The pefCD genes are
annotated in GAS genome as the subunits of a putative multi-drug resistance (MDR)
system. Sequence analysis indicated that the pefCD genes code for the two subunits of a
heteroligomeric ATP-dependent exporter. Both ORFs contain, at the N terminus, an
integral membrane (IM) permease domain from the superfamily of ATP binding cassettes
fused to an ATP-hydrolyzing domain (ABC, also referred to as the nucleotide binding
domain) (Figure 21B). This domain organization is of the Class-1 ABC-type transporter
family (252). This transporter class is comprised of systems with fused IM and ABC
domains and contains the vast majority of ABC-type export systems (252). Our recent
BLAST

analysis

against

the

transporter

classification

(TC)

database

(http://www.tcdb.org) (253) revealed that the PefCD proteins consists of a transporter
from the drug exporter-4 sub class (3.A.1.135). Importantly, this analysis revealed that
PefCD exporter is identical to a previously described transporter from the GAS strain
JRS4, named Rsc (regulated by stress and Cov) after its regulation by the response
regulator CovR (254). The substrate(s) of the Rsc system was not identified but the
transporter was found to be required for bacterial growth at high temperature. The nearest
relatives of the PefCD (RscAB) proteins are the components of the MDR transporters,
SatAB of S. suis (255), PatAB from S. pneumonia (256), and LmrCD (aka YdaG and
YdbA) from L. lactis (257). For simplicity we continue in this manuscript to refer to the
GAS exporter as the PefCD system. Further in-silico analysis performed on genomes of
streptococci identified putative homologs of the pefRCD gene cluster in S. equi, S. uberis,
S. suis, and S. iniae (258-262). A high degree of conservation in genetic organization and

72

sequence exhibiting 54% amino acid similarity for the PefR, 60% for the PefC, and 64%
for the PefD protein among all the candidates tested by ClastalW pairwise alignment tool
(263), (Figure 21A).

5.3.2

Inactivation of pefCD resulted in a growth phenotype and hypersensitivity
to heme and doxorubicin.

In order to gain insight into the role of the pefCD genes in GAS physiology, we created a
polar mutation in pefC by insertion inactivation (ZE4951 strain) in the background of the
wild type strain, NZ131 (Table 6 and Figure 22A). For complementation of pefCD polar
mutation, we cloned the pefRCD operon with its native promoter into a shuttle vector
(pKSM201). E. coli cells harboring the plasmid carrying the GAS pefRCD operon
(pANKITA5b) did not exhibit any growth phenotype. However, despite our multiple
attempts, we failed to create a sub clone that expresses only the pefCD genes (under the
pef promoter). We therefore used the entire pefRCD operon (carried by pANKITA5b) to
complement the ZE4951 mutant. Analysis of ZE4951 growth in THYB media
demonstrated that inactivation of the pef system resulted in a pronounced phenotype; the
mutant cells grew slower and reached the stationary phase of growth at a lower cell
density in comparison to the isogenic NZ131 wild type strain (Figure 22B). In addition,
cell viability of the mutant strain was significantly reduced during overnight incubation in
stationary phase (data not shown). The growth defect of the ZE4951 mutant was reversed
in the presence the pefRCD genes expressed in trans (pANKITA5b) but not in the
presence of an empty shuttle vector (pKSM201, Figure 22). This analysis suggests that
the pefCD genes are required for optimal GAS growth in standard laboratory medium.
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When tested for heme sensitivity, the ZE4951 mutant strain exhibited a larger zone of
clearance around a heme-submerged disc compared with the wild type strain (Table 8).
The mutant sensitivity to heme was restored to the wild type level when complemented in
trans with the pefRCD genes, but not in the presence of the control plasmid. These
observations supported the hypothesis that PefCD consists an efflux system that extrudes
heme or heme-related toxic metabolites. While some exporters are selective for a given
substrate, many are able to expel a range of structurally unrelated molecules (93, 252).
Examining the growth of the mutant strain around discs containing the anthracyclic
compound, doxorubicin, revealed increased sensitivity compared with the parent strain
(Table 8). As with the sensitivity to heme, the doxorubicin hypersensitivity phenotype
was reversed when the pefRCD genes were supplied in trans (Table 8). Heme and
doxorubicin are structurally dissimilar; these data are consistent with the in silico analysis
described above and imply that PefCD is an exporter with a broad substrate specificity.

5.3.3

Inactivation of the pefCD system is associated with elevated levels of
heme-induced damage to cellular constituents

In order to uncover why the loss of the pefCD genes leads to reduced heme tolerance in
GAS, we investigated the impact of heme on GAS cellular components in the wild type
and mutant strains. In a recent study we demonstrated that exposure to low heme
concentration was sufficient to damage the lipids in GAS envelope (50). Oxidized lipids
react with a thiobarbituric acid (TBA) reagent to form adducts (named TBARS) that can
be monitored by spectroscopic methods and quantify with a standard curve (50, 201). We
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compared the time course of TBARS formation between the wild type and mutant strain
after the addition of 1 μM heme into the culture (Figure 23). Analysis of samples
collected 30 minutes post exposure revealed that the ZE4951 mutant exhibited higher
level of lipid damage than the wild type strain (3 versus 1.5 nmol/ml TBRAS in the
mutant and wild type strain respectively). Complementation of the pefC mutation with
the pefRCD genes resulted in a significantly lower level of TBARS formation, in
comparison to mutant cells harboring the negative control plasmid (0.97 and 2.49
nmol/ml respectively). Interestingly, the TBARS levels in the complemented mutant
strain were reduced over time (from 0.98 to 0.38 nmol/ml in the 30 and 90 min samples
respectively), while they remained approximately the same in the wild type, mutant, and
the mutant cells harboring the control plasmid. Together these observations imply that the
PefCD system defends GAS from heme-induced lipid damage and suggest that the
expression of pefRCD genes under our experimental conditions may be limiting in the
wild type strain.

Studies performed with eukaryotic systems showed that heme could harm nucleic acids
(264). We asked if environmental heme can damage GAS genome and if the pef system
offers protection from this harm. The repair of chemically altered bases (due to oxidation,
deamination or alkylation) in the DNA is often mediated by repair mechanisms that
involve the formation apurinic/apyrimidinic (AP) sites. Therefore, the amount of AP sites
serves as a good indicator for DNA damage and repair. To quantitate the formation of AP
sites in GAS chromosome, we used a reagent (ARP) that reacts specifically with the
aldehyde group in the open ring form of the AP sites (265). Chromosomal DNA was
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extracted from culture samples that were harvested at different time points and was
allowed to react with ARP reagent. The formation of AP sites was detected by ELISA
and quantified using a standard curve (Figure 24). Analysis of chromosomal DNA from
culture samples of the wild type strain collected 30 minutes after the addition of heme
revealed about 90% increase in the number of AP sites compared to the background level
(11 and 5.8 AP sites per 105 bp respectively). The AP sites level was reduced over time,
but remained 40% above the background (8 AP sites per 105 bp) in the samples collected
90 minutes after treatment. Interestingly, in pefC mutant the background level of AP sites
was about twice as high compared with the wild type strain (11.5 AP sites per 105 bp).
Heme exposures resulted in a transient 117% increase in the number of AP sites, which
was reduced to background level within 60 minutes (25 and 11.5 AP sites per 105 bp in
the 30 and 90 minutes respectively). The high AP levels observed in the mutant strain
were complemented to those observed in the wild type strain by the pefRCD genes
expressed from a plasmid in all samples. The levels of AP sites in the mutant strain
carrying the empty vector were comparable to that of the mutant strain alone. These
experiments indicate that environmental heme led to DNA damage in GAS and that the
pefCD genes offered protection from DNA damage during growth in laboratory medium
as well as in medium containing externally added heme. In addition, our data highlights
the presence of DNA repair mechanisms in GAS.

5.3.4

The pefCD prevents cellular heme accumulation

One interpretation of the experiments described above is that following the addition of
heme to the culture medium GAS cells absorb it in surplus amounts; in the absence of a
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functional PefCD system, the bacterium accumulates heme or heme-related metabolites
that damage the cell constituents. To directly test this hypothesis, we examined the
cellular heme content by the acidified chloroform extraction method (251) described in
the material and methods (Figure 25). Culture samples of equal cell density were
collected 90 minutes after the addition of 3 μM heme to the medium and the cells were
washed extensively to remove surface bound heme prior to heme extraction. The
presence of heme in the organic phase of the cell extracts was examined by spectroscopic
analysis and the concentration of the extracted heme from each sample was extrapolated
from a standard curve (Figure 25B and 25D). We extracted in these experiments about
30% more heme from the pefC mutant in comparison to the wild type strain. The heme
concentration obtained from cells of the pefC mutant complemented with the pefRCD
genes, was 7% lower than that extracted from the wild type cells. On the other hand, the
presence of the empty vector did not have a significant impact on the heme concentration
in the extract from the pefC mutant. Therefore, the PefC accumulates more heme then the
wild type strain. This observation suggets that the PefCD system expels surplus heme
from GAS cells.

5.4

Discussion

Heme is an important nutrient for the β-hemolytic GAS, which uses it in order to obtain
iron within the host environment (131). Despite its nutritional value, heme is a harmful
molecule, damaging to GAS envelope even in low concentrations (50). In the current
study, we investigated how GAS manages the toxic challenges imposed by environmental
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heme. We recently identified a 3-gene operon that was induced by heme and named it
after the pefRCD system in GBS (50, 95). Following up on our initial observations, we
carried out a functional characterization of the pefCD genes in the GAS strain, NZ131.
We established that they play an important role in heme tolerance; defending GAS
membrane and chromosome from the toxic effects of heme stress and prevents heme
accumulation in the bacterial cells. This is the first heme tolerance pathway to be
described in GAS.

To examine the role of the pefCD genes in GAS, we created a polar mutation in pefC,
which we then supplemented with the pefRCD expressed from a plasmid. All of the
observed phenotypes of the pefC mutant were effectively complemented, indicating that
under our experimental conditions, the PefCD proteins were expressed in trans at
sufficient levels despite the presence of the putative repressor, pefR, on the
complementation plasmid. Our failed attempts to clone pefCD under the native pef
promoter in the absence of pefR raises the possibility that the constitutive expression of
the pefCD genes is detrimental to E. coli. Toxicity of membrane proteins when
overexpressed or of proteins expressed in heterologous host is not uncommon. A similar
problem was reported for the related SatAB system of S. suis (255).

Examining the phenotype of the pefC mutant and the complemented strain showed that
the loss of the PefCD system led to increased sensitivity to heme and doxorubicin (Table
8). This observation is consistent with the bioinformatics analysis that revealed
significant similarity among PefCD proteins and the confirmed MDR transporters SatAB,
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PatAB, and LmrCD from S. suis, S. pneumoniae and L. lactis respectively (255, 257,
266). Together, these observations imply that the PefCD proteins consist of a MDR
transporter that expels doxorubicin and heme or heme related metabolites. Our additional
findings demonstrated that GAS accumulates heme in the absence of a functional PefCD
transporter (Figure 25), strongly implicating heme as a substrate of the pefCD system.
The pefC mutant exhibited growth attenuation in THYB (Figure 22B). THYB contains
infusions of brain and heart tissues. Therefore, the mutant growth phenotype might have
resulted from increased sensitivity to the heme that is already present in the medium.
Alternatively or in addition, PefCD may help in the clearance of other toxic molecules
that are generated during growth. Interestingly, a previous study performed in the JRS4
strain revealed that the pefC (rscA) gene is induced at low pH and by heat stress and that
a pefC mutant could not grow at 40 °C. The growth phenotype at a high temperature
raised the possibility that the pefCD proteins export molecules that harm the membrane
structure and fluidity (254). Heme could be such a molecule, since it is known to
penetrate membranes and undermine the membrane permeability (245, 267).
Alternatively, other compounds exported by PefCD may be responsible for this
phenotype.

We previously reported that the addition of 4 μM heme to the culture medium produced
oxidative damage in the envelope of the invasive MGAS5005 strain (50). In this work,
we made similar observations with the nephritogenic NZ131, and showed that exposure
to 1 μM heme led to noticeable levels of lipid peroxidation (Figure 23B). Moreover, we
showed for the first time that externally added heme (5 μM) is also damaging to GAS
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chromosome (Figure 24B). Together, these observations highlight the destructive impact
of environmental heme on GAS cellular components even at relatively low
concentrations. A number of observations demonstrate the importance of the PefCD
system in heme detoxification and suggest a positive correlation between the expression
of pefCD system and detoxification capacity: 1) The pefC mutant experienced more lipid
and DNA damage comparing with the wild type strain after heme treatment (Figure 23B
and 24B). 2) The level of lipid peroxidation in the wild type strain remained constant for
30-90 minutes post treatment, while it was reduced over time in the complemented strain
(Figure 23B). 3) More AP sites were detected in the chromosome of the pefC mutant
comparing to the wild type strain even in the absence of externally added heme. 4) Heme
begins to accumulate in the mutant cells after its addition to the growth medium (Figure
25D). The pef regulon in GBS is induced by levels of heme that are lower than those
required to fully activate the putative HrtAB transporter; it was therefore suggested that
the Pef exporters allow for adjustments in small variations in heme and PPIX
concentrations under different physiological conditions while the Hrt exporter may be
needed to defend GBS against higher heme concentrations (95). Here, we established
that the PefCD system in GAS is responsive to low levels of environmental heme (1-5
μM) and participate in the detoxification process. We did not identify HrtAB homologues
in GAS, but it is possible that additional transporter(s) in GAS are recruited at higher
heme concentrations.

GAS is a versatile pathogen that exhibits wide tissue tropism and adaptability that
enables it to inhibit not only the epithelia of the skin and mucous membranes, but also to
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flourish within soft tissues, the lymphatic system, and the blood (4). Therefore,
depending on the nature and stages of infection, GAS is expected to confront a wide
spectrum of heme concentrations, ranging from low amounts (e.g., during simple skin or
mucosal infection) to very high concentrations (such as during invasive infections
associated with significant erythrocyte lysis and tissue destruction). Furthermore, heme
tolerance varies among GAS isolates with highly invasive strains such as MGAS5005
showing higher resistance (Heme MIC = 50 μM) than strains that are typically associated
with local infections such as NZ131 (MIC = 10 μM) (50). We propose that the PefRCD
represent a fundamental heme defense pathway that is shared by all GAS strains,
safeguarding the organism against environmental heme. Highly invasive strains may
carry additional pathway(s) that might confer increased resistance.

The role of active export in the management of heme (and other porphyrins) levels and
toxicity in bacterial systems is not fully appreciated and only few systems have been
described up to date. Two systems were identified in Gram-negative bacteria
(MacAB/TolC and MtrCDE for E. coli and N. gonorrhoeae, respectively) (239, 242,
268). Both exporters consist of cytoplasmic transporters that connect via a membrane
fusion protein to an outer membrane channel/tunnel protein. Both cytoplasmic
transporters are MDR systems that export a number of compounds in addition to heme
and/or porphyrins. However, MacAB is an ATP-type transporter while MtrC belongs to
the Resistance/Nodulation/Division (RND) family of transporters, which uses the proton
motive force for energy-dependent export. In Gram-positive bacteria, four types of
energy dependent exporters used for heme and/or PPIX detoxification were described
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(Figure 26). Intriguingly, HrtAB, which was first identified in S. aureus (244), belongs to
the MacAB family of ABC-type efflux carriers. In this family of ABC transporters, the
membrane permease (IM) and the ATPase (ABC) domains are encoded by separate
polypeptides (Class 3) (252). HrtAB mediates heme tolerance in a number of Grampositive bacteria. It was shown to pump heme directly out of the membrane compartment
in L. lactis (245) and it is likely that it functions in a similar manner in the other Grampositive species. In L. monocytogenes, a P-Type ATPase, that displays homology to
bacterial heavy-metal transporting ATPases, confers resistance to heme and hemoglobin
(247). The two other types of transporters were described first in GBS: PefAB
(antiporter) belongs to the MFS family that relies on the proton motive force and PefCD,
which is a Class I, ABC-type transporters (95). In this study, we showed that the GAS
PefCD system contributes to tolerance against both heme and doxorubicin. The
involvement of the other transporters from Gram-positive bacteria in resistance to
compounds other than porphyrins was not examined. We established significant
orthology between the GBS PefCD and the system encoded by GAS. Moreover, our in
silico analysis suggests that the previously described SatAB transporter from S. suis is an
orthologous system and that a pefRCD–like operon is also found in the members of the
pyogenic streptococci. In GBS, the PefCD proteins export heme and PPIX (95). Our
work here illustrates that this transporter in GAS exports heme and doxorubicin. The S.
suis, SatAB, is a narrow-spectrum fluoroquinolone exporter (norfloxacin and
ciprofloxacin) (255). It will be interesting to find out whether the PefCD system is a
MDR transporter that has heme as one of its substrates or if it has evolved distinct
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substrate specificities among various species reflecting differences in ecological niches
and lifestyle.
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APPENDIX
Appendix A: Tables
Table 1: Strains and plasmids used in chapter 2
Name

Description

Reference

E.coli Top10

Host for pZZ2 propagation

Invitrogen

E.coli BL21 Star

Host for pZZ2 expression

Invitrogen

pET101/D-TOPO

Directional TOPO® TA cloning

Invitrogen

pOM101

vector

(135)

pZZ2

Expresses Shp-His tag from PT7

This study

Strains

Plasmids

Expresses HupZ-His tag from
PT7

Table 2: Crystallographic data collection and refinement statistics

PDB Code
Space group

4NU4
P1

Cell Dimensions

102

a (Å)

41.82

b (Å)

61.18

c (Å)

61.35

 ()

78.59

 ()

86.76

 ()

80.07

Molecules/asymmetric unit
Resolution range

4
50.0 – 2.0

Total observations

142558

Unique reflections

39089

Completeness

98.2 (97.7)a

<I/(I)>

13.6 (7.7)

Rsym (%)

9.9 (37.7)

Refinement resolution range

50 – 2.0

Rcryst (%)

17.0

Rfree (%)

21.7

Number of solvent

270

Mean B-factor (Å2)

24.7

RMS deviations from ideality
Bond length (Å)

0.03

Angles ()

2.2

a

Values in parentheses are given for the highest resolution shell (2.00-2.03 Å)
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Table 3: Strains used in chapter 3

Name

Description

References

Strains
MGAS5005

GAS (M1), isolated from cerebrospinal fluid

NZ131

GAS

(M49)

isolated

from

acute

(199)

post- (197)

glomerulonephritis infection
GA01398

GAS (M11).

GA-EIP*

GA06439

GAS (M114)

GA-EIP*

GA02581

GAS (M1)

GA-EIP*

GA02582

GAS (M1)

GA-EIP*

GA10156

GAS (M75)

GA-EIP*

COL (MRSA)

S. aureus, clinical specimen isolated from (269)
operating theater in England

E. cloni® 10G Host for pAJS11 propagation and expression

Lucigen

Plasmids
pRham™ NHis

Protein expression vector, KanR, expressed from Lucigen
rhaPBAD
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pAJS11

Expresses N-Terminal His-tag PefR, KanR

This study

*Georgia Emerging Infections Program (GA-EIP)

Table 4: Primers used in chapter 3

Target

PCR primers

Sequence (5'-3')

pefR ORF

ZE515

CATCATCACCACCATCACTCACAAGTG
ATAGGTGATTTACG

ZE516

GTGGCGGCCGCTCTATTAAGCATCGTTG
TCTCCTTTATAA

Ppef

pefR

pefC

rpsL

prsA

ZE561

AAGGCGTTCCCAAGAGAGCTAG

ZE562

CCTTGAGGACCTGCTAGATGCTCTAC

ZE569

CAATGTGATGCCTTCCCAAG

ZE570

CGCTGTCAGCAACTCTTC

ZE571

CCTCATCATGGGTTTGGTG

ZE572

ACGCCACGGAGATTTTCC

ZE581

CAGATTCACCAGCTTTGAAC

ZE582

CAACACGAGTAGCAACG

prsA-M1-RT-L

GGGCAGACTTTGCAGCTATTG
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clpL

opuAA

endoS

ptsA

sagA

spt7R

slo

prsA-M1-RT-R

TCGCCTGAGTCAAACGTATAGG

clpL-M1-RT-L

TGGCTTGAGCTAAACCTTCA

clpL-M1-RT-R

CTTGGCACGACGAACTAAAA

opuAA-M1-RT-L

TGATTTGCAAGACAGCATGA

opuAA-M1-RT-L

CATCAAAGCAATCCGATCAC

endoS-M1-RT-L

CTCGGTCAATAGCGTAGGAGAAG

endoS-M1-RT-L

GCGTGCCGAACGGTATG

ptsA-M1-RT-L

TTTTTTAAAACCAGGCGAAGC

ptsA-M1-RT-L

TTGTCTCAGGGACCAAATCC

sagA-M1-RT-L

GCTACTAGTGTAGCTGAAACAACTCAA

sagA-M1-RT-L

AGCAACAAGTAGTACAGCAGCAA

spt7R-M1-RT-L

TCATTTGCGGCTGAAATAATAATG

spt7R-M1-RT-L

GCAATGGGATTCAATTTTTGGA

slo-M1-RT-L

TTGTTGAGGATAATGTAAGAATGTTTA
G

fasC

mtsA

slo-M1-RT-R

TCCTGGCTTGCAACTGATTG

fasC-M1-RT-L

TGCGCACAAATTATGAAATATCTTC

fasC-M1-RT-R

GAGCTTCAAGCAATTTGGAATTC

mtsA-M1-RT-L

TGAGGGTCTTGACCGATTG

mtsA-M1-RT-R

AAGTCGTGGCAACCAATTC
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Table 5: Bacteriostatic effect of heme

Agar dilution

Broth dilution

Disc diffusion

Straina

(μM)

(μM)

(mm)

NZ131 (M49)

10

10

9

GA01398 (M11)

20

30

1.25

GA06439 (M114)

20

30

6.75

GA02581 (M1)

20

50

6

GA02582 (M1)

15

50

4.75

GA10156 (M75)

20

30

4.5

MGAS5005 (M1)

20

50

5.5

S. aureus (control)

260

80

4.25

The minimal heme concentration that inhibits bacterial growth (MIC) was determined by
the methods of agar dilution and broth macrodilution. The growth inhibitory effect of
heme is also expressed as the clearance zone around heme impregnate discs (10 mM).
See material and methods for details. Data are representative of two independent
replicates.
a

GAS M type (if available) is indicated in parentheses
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Table 6: List of bacterial strains and plasmids used in chapter 4.

Strain name

Characteristics

References

M49 serotype isolated from

(197)

S. pyogenes
NZ131

acute postglomerulonephritis
infection
ZE4951

NZ131 derivative with

This study

pefC::pMZ1 mutation
ZE4951/pANKITA5b

ZEM4951 strain

This study

complemented with pefRCD
locus expressed from
plasmid pANKITA5b
ZE4951/pKSM201

ZEM4951 strain harboring

This study

the pKSM201 vector
E. coli
DH5α

hsdR17 ecA gyrA endA1

(270)

relA1
Plasmids
pMZ1

pUC-Spec derivative

This study

containing pefC internal
fragment and the spec
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resistance gene aad9
pKSM201

Shuttle vector containing

(250)

the kanamycin resistance
gene aphA3
pANKITA5b

pKSM201 derivative

This study

carrying the pefRCD genes

Table 7: List of primers used in chapter 4.

Sequence (5’-3’)

Source

EcoR1

GGGGAATTCTTATGGTGGGTCATTGTTG

This study

EcoR1

AATGAATTCTAAGCGAGGGATGAGCTGT This study

Primers

Restriction

name

site

(Target)
ZE565
(pefC)
ZE566
(pefC)
ZE634

G
SpeI

(pefRCD)
ZE635
(pefRCD)

AAGGACTAGTGGTCTTGGCTAATAAGGC

This study

G
SpeI

AGGGACTAGTTTGGGATTCATGTTAGCG

This study

AG

Table 8: Determination of heme and doxorubicin sensitivity by disc diffusion assay
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Strain Name

Zone of clearance (mm)
Heme

Doxorubicin

WT (NZ131)

11.8±1.37

16

Mutant (ZE4951)

15.8±1.53a

23±1.25c

Complement (ZE4951/pANKITA5b)

9±0.23

17±0.19

Control (ZE4951/pKSM201)

13±0.31b

22±1.27d

The letters a, b, c, and d represent P values of statistical significance at 0.05 levels of
significance calculated using student t-test (of equal variance). The statistical significance
was evaluated by comparing WT with Mutant & Complement with Control data set.
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Appendix B: Figures

FIGURE 1.

Figure 1: Iron homeostasis. The fate of the acquired iron in the human body depends
upon the physiological needs and stimuli resulting in transfer or storage of the metal (see
text for details). This figure is adapted from (271).
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FIGURE 2.

Figure 2: The structure of porphyrin-heme. The B form of heme (Fe+2-PPIX) or hemin
(Fe+3-PPIX) is a macrocyclic compound that consists of four tetrapyrrole rings (depicted
as A, B, C, and D) held together by four methine bridges (α, β, γ, and δ). The nitrogen
atoms of tetrapyrrole can coordinate metal iron that can take part in various biochemical
reactions.
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FIGURE 3.
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Figure 3: Spectral features of heme-porphyrin. A typical UV-visible spectra for PPIX,
free heme, and heme bound protein (PefR, from GAS).
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FIGURE 4.

Figure 4: Catalytic intermediates of heme degradation by HO-1 The regiospecific
degradation of ferric heme (which absorbs at the Soret region) involves oxygenation
leading to formation of transient and highly unstable ferrous-hydroperoxyheme, which
self-stabilizes by hydroxylation reaction on the edge of a tetrapyrrole. The hydroxylated
ferric heme after undergoing second oxygenation reaction leads to release of CO and
formation of ferrous-verdoheme. The verdoheme upon final oxygenation yields ferric
biliverdin with the opening of macrocyclic structure. Ferric biliverdin through gain of
protons releases iron and produces a chromophore biliverdin (which absorbs between 640
to 680 nm).
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FIGURE 5.

Figure 5: Heme degradation pathway catalyzed by HO-1 (272).
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FIGURE 6.

Figure 6: HupZ is a heme binding protein. Counter-clockwise: A. SDS-PAGE
showing purified recombinant HupZ next to molecular markers. B. UV-visible absorption
spectrum of 10 M HupZ as purified from E. coli and the heme-bound form (heme-
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HupZ) in SPB. The UV-visible absorption spectrum of 5 M heme is included. A sample
containing only SPB was used as a blank. C. UV-visible absorption spectrum of HupZ as
purified (in SPB) from E. coli grown in the presence of 5-aminolevulinic acid. The FPLC
purified fraction is documented in inset. D. Differential absorption spectroscopy of hemeHupZ complex. Increasing amounts of heme were added at final concentrations of 1, 2, 4,
6, 10, 12, and 14 M to both the blank and apo-HupZ (10 M). The insert shows the
stoichiometry of heme binding to HupZ. The changes in absorbance at 414 nm were
plotted against heme concentration, defining a 1:1 stoichiometry with tight binding. The
data are representative of at least two independent spectroscopic analyses.
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FIGURE 7

Figure 7: Heme degradation by HupZ. A. Heme degradation in the presence of CPR
and NADPH. UV-Visible absorption spectra were recoded before and at 10, 20, 30, 40,
50 and 60 min after the addition of 250 μM NADPH to 10 M Holo-HupZ and 0.4 M
CPR in SPB. SPB containing all reaction components other than HupZ and NADPH was
used as a blank. B. Heme degradation in the presence of CPR and NADPH regeneration
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system. The same as in A, except that the reaction contained 100 μM NADPH, 6.5 mM
glucose-6-phosphate, and 1 unit of glucose-6-phosphate dehydrogenase as NADPH
regeneration system. UV-Visible absorption spectra were recoded before and after the
addition of NADPH, at 10 min intervals for 1 h, and then every 60 min for additional 5 h.
C. The spectral changes insert demonstrates the changes in absorbance at 414 and at 660
nm over time for every hour. Catalase (2 μM) was included in all of the reactions. The
data are representative of at least two independent spectroscopic analyses. D. Control
reactions for HupZ heme degradation. For Shp control, 20 μM holoShp was incubated
with 0.4 μM CPR, 500 μM NADPH and 2 μM catalase in SPB (pH 7.4). Spectral changes
were recorded at 25 °C for 60 min. For free heme control: 10 μM of hemin chloride was
incubated with 0.4 μM CPR, 2 μM catalase and 100 μM of NADPH with regeneration
system in SPB (pH 7.4). Spectral changes were monitored every 60 min for 6 h at 25 °C.
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FIGURE 8.

Figure 8: Evaluation of heme degradation by HupZ using FNR-Fdx as reducing
equivalent. UV-visible absorption spectra were recoded before and at 10, 20, 30, 50 and
60 min after the addition of 500 μM NADPH to 20 μM Holo-HupZ, 10 μM spinach Fdx,
0.1 unit/mL spinach FNR and 2 μM catalase, in 1 mL SPB. The reaction spectra were
recorded using SPB as blank.
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FIGURE 9.

Figure 9: Differential absorption spectra of holoHupZ reaction in the presence of
myoglobin. Myoglobin (4 M) was added to a sample containing holoHupZ (5 M), 0.4
M CPR and 2 M catalase in SPB. The spectra were recorded before and after the
addition of 500 M NADPH at 30 s intervals for 16 min. SPB containing all reaction
components other than myoglobin and NADPH was used as a blank. The control reaction
was carried out in a similar manner, except without HupZ. The insert shows the
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absorption changes at 410 (experiment and control) and 420 (experiment) nm over time.
The data are representative of at least two independent spectroscopic analyses.
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FIGURE 10.

Figure 10: Differential absorption spectra of holoHupZ reaction in the presence of
ferrozine. A. Heme degradation by holoHupZ (20 M) was carried out in SPB
containing CPR (0.4 M), 200 M NADPH with regeneration system, ferrozine (1 mM),
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and catalase (2 M). UV-visible absorption spectra were recorded before and 12, 18, 30,
42, 48, 60 min after the addition of NADPH and then every 60 min for 5 h, and an
additional time point was taken after 22 h. SPB containing all the reaction components
other than holoHupZ and NADPH was used as a blank. As a control, heme (20 M) was
incubated in sample buffer with ferrozine and catalase. B. The absorbance changes over
time at 414 (heme degradation) and 564 (iron-ferrozine complex) nm in the sample and
control reactions (for free hemin) at 410 nm were recorded. The data are representative of
at least two independent spectroscopic analyses. C. Titration of ferrozine with ferrous
iron. 250 μM of ferrozine was incubated with an increasing concentration of FeSO4 (0.1,
0.5, 1, 5, 10, 20, and 50 μM) solution in SPB in a 1 mL final volume and spectral changes
were recorded. The standard curve was obtained from plotting the increase in absorbance
at 564 nm against the ferrous iron concentration.
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FIGURE 11.

Figure 11: Crystal structure of HupZ. A. Structure of HupZ homodimer. The two
monomers are colored in red and green. B. The split barrel fold of HupZ monomer
with the three -helices and six β-strands labeled. C. Superposition of HupZ (red)
with HugZ (yellow). The heme binds to the extended C-terminal end of HugZ, which
appears to be truncated in HupZ. His245 near the C-terminal end is involved in heme-Fe
coordination and conserved across other split barrel heme oxygenases. The Arg166
important for enzymatic activity of HugZ is substituted by glycine on secondary structure
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matching. Heme, Arg166, His245 and azide from the HugZ structure are shown in stick
representation and colored by element type in C and D. D. Superimposed structures of
HupZ (red) and ChuZ (cyan). ChuZ binds two heme moieties. The first heme binds at
the flexible C-terminal end of the split barrel domain similar to HugZ with similar
coordination, while the second heme binds at the N-terminal domain, which is absent in
HupZ.
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FIGURE 12.

Figure 12: Phylogenetic tree of HupZ with other heme degrading enzymes. The tree
was obtained from multiple sequence alignment in ClustalW (273). We used neighborjoining method for tree construction and bootstrap analysis (parameter set at 1000
resampling) preformed using MEGA win-5.21 software (274). The locus tag or the
accession number for each protein used in the sequence alignment is as follows: HupZ
locus tag: Spy_0844 [S. pyogenes M1 GAS]; IsdG locus tag: NWMN_1047 [S. aureus
subsp. aureus str. Newman] ; IsdI locus tag: NWMN_0111 [S. aureus subsp. aureus str.
Newman]; HugZ locus tag: HP0318 [H. pylori 26695]; HutZ locus tag: VCA0907 [V.
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cholerae O1 biovar El Tor str. N16961]; PigA (Pa-HO) locus tag: PA0672 [P.
aeruginosa PAO1]; HmuO locus tag: CDC7B_1652 [C. diphtheriae C7(beta)] ; HO-1
locus tag: CTA-286B10.6 [Homo sapiens]; MhuD locus tag: Rv3592 [M. tuberculosis
H37Rv]; HemS accession number: P31517 [Y. enterocolitica]; ChuS locus tag:
E2348C_3742 [E. coli O127:H6 str. E2348/69]; PhuS accession number: AF055999 [P.
aeruginosa PAO1]. Bootstrap units were obtained from 500 repeats of neighbor joining
using the MEGA win-5.21 software.
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FIGURE 13

Figure 13: Heme exposure leads to lipid peroxidation in GAS. A. Cell growth.
MGAS5005 cells growing in C-medium were treated with 4 μM heme in 0.035% DMSO
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(Heme) or with mock treatment (0.035% DMSO, Control) at the early logarithmic growth
phase. Culture samples were harvested 30, 60 and 90 min post exposure and processed.
B. Malondialdehyde (MDA) standard curve. 100

l samples of MDA at a concentration

of 0, 12.5, 25, 50, and 100 nmol/ml were allowed to react with thiobarbituric acid (TBA,
see material and methods). The absorption at 532 nm of the supernatants from processed
samples was determined and plotted as a function of MDA concentration exposure. The
linear equation obtained for the standard curve was y = 0.0059x with R2 value of 0.9997.
C. Lipid peroxidation following heme exposure. Cell lysates were prepared and allowed
to react with TBA. The sample absorption at 532 nm was determined and the formation
of TBA-reactive-substances (TBARS) was calculated using the standard curve shown in
B. All samples were standardized with respect to the cell number in the corresponding
culture. Data are representative of biological triplicates.
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FIGURE 14.

Figure 14: Protein oxidation following heme exposure.
The membrane (A) and cytoplasmic proteins (B) extracted from cells harvested at
different time points post treatment were allowed to react with DNPH (see material and
methods) before fractionation by SDS-PAGE. Sample identity (H for heme treated cells
and C for controls) and collection times (30, 60 and 90 min) are indicated [top panel].
Western blot with anti-DNP antibodies (OxyBlot) developed by chemiluminescence
[bottom panel]. Coomassie blue-stained gel. All samples were standardized with respect
to the cell number in the corresponding culture. C. Quantification of protein oxidation.
The reaction with anti-DNP antibody in each membrane sample was quantified by
densitometry. Arbitrary values for the heme treated samples (Heme) and mock treated
(Control) after background subtraction are plotted. Error bars are shown. Data are
representative of biological triplicates. Note that the western blot showing larger spots in
an area outside of the lane is a technical artifact associated with the film development and
it’s not a true reaction (prominent in Figure 9B, top panel).
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FIGURE 15.

Figure 15: GAS employs an adaptation strategy to avert growth phenotypes
associated with heme stress. NZ131 cells were grown overnight in C-medium
supplemented with 0.1 μM (adapted culture) and without heme (non-adapted culture).
The overnight cultures were used as an inoculum to monitor growth in presence and
absence of heme. Briefly, non-adapted culture was grown in C-media supplemented with
0 and 1 μM heme, whereas adapted culture was sub-cultured into C-media containing 0.1
and 1 μM heme. The growth was monitored colorimetrically for 8 hours at 37 °C.
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FIGURE 16A

Figure 16 A: Genes responding to heme stress in M1T1 GAS strain MGAS5005.
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FIGURE 16 B

Figure 11 B Genes responding to heme stress in M1T1 GAS strain MGAS5005.

Total RNA was extracted 90 min post treatment and analyzed by microarray. A. Genes
repressed or activated following exposure to 4 μM heme (in 0.035% DMSO) compared
with mock treatment (0.035% DMSO). Data for genes whose expression was
significantly different between cells exposed to heme and those subjected to mock
treatment were combined and assigned to categories. B. Selected heme-activated genes
revealing protein and redox stress response. Values represent relative expression levels
(fold-change) in heme treated bacteria compare with mock treatment.
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FIGURE 17.

Figure 17: Multiple sequence alignment of PefR amino acid sequence from GBS and
GAS. The degree of homology between GAS PefR (encoded by MGAS5005 spy_0195)
and GBS PefR (encoded by gbs1402) is depicted in pair-wise sequence alignment
performed using ClustalW. The amino acids are represented by single letter code. The
symbols: (*) indicate identical residues; (:) indicate strongly similar residues; (.)
designate weakly similar residues. An accuracy of alignment was also confirmed using
MUSCLE tool (275) that showed identical alignment output as well.

135

FIGURE 18.

Figure 18: The streptococcal pefRCD locus. A. Genetic organization of the pefRCD
gene cluster in GAS. The putative PefR binding identified in silico and its homology to
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the PefR binding motif from GBS (95) are shown. B. Time course of pefRC expression
in response to heme stress. Total RNA was extracted at different time points following
heme or mock treatment and the relative expression of the pefR and pefC genes was
evaluated by Real-time quantitative RT-PCR.
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FIGURE 19.

Figure 19: The PefR from GAS is a heme binding protein. A. A Coomassie bluestained gel showing purified recombinant PefR from GAS next to a molecular marker. B.
Heme titration of PefR. UV-visible spectrum of 10 M PefR (in SPB) following
incubation with an increasing concentration of hemin chloride (2-30 M) in 2 M
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increments. SBP with the corresponding heme concentration was used as blank and
subtracted from the sample spectrum. Heme binding by PefR is indicated by the
increased absorption at 435, 530 and 560 nm. The arrow indicates the direction of the
absorption changes. The images are of PefR as-purified from E. coli and of holo-PefR
(after heme reconstitution and removal of heme excess by gel filtration and dialysis). This
data represents three independent heme-titration experiments. C. Stoichiometry of heme
binding to PefR. The changes in absorbance at 435 nm were plotted against heme
concentration. The Kd was determined by fitting the data into modified hills equation for
multiple binding sites (215). The Kd equals 10 M and nH (hill’s coefficient) is 1.37 M.
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FIGURE 20.

Figure 20: The PefR is capable of PPIX binding. A. PPIX titration of PefR. Change in
the UV-visible spectral profile of 5 M of PefR (in SPB) when titrated with an increasing
concentration of PPIX (0.25-6 M) in 0.5 

increments was monitored across

wavelength (300 – 700 nm). Free PPIX spectrum (shown in black) showed absorbance
peaks in 432, 521, 556, 596, 655 and 685 nm regions. The PefR bound PPIX
demonstrated maximum absorbance at 437 and 686 nm; absorbance at these wavelengths
showed increase with PPIX concentrations (0.25 - 6 M; shown in different colors). The
arrow indicates the direction of the absorption changes. B. Stoichiometry of PPIX
binding to PefR. The spectral changes at 437 nm were plotted against PPIX
concentration. The Kd was determined by fitting the data into linear equation.
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FIGURE 21.

Figure 21: The prevalence of the pefRCD operon in human and zoonotic
streptococci. A. The genomic arrangement and occurrence of the pefRCD genes in GAS
(MGAS5005 strain) and GBS (NEM316 strain) is also conserved among members of the
pyogenic cluster namely, S. equi (4047 strain), S. uberis (0140J strain), and S. iniae
(ISET0901). Additionally, this system is found in S. suis (JS14 strain). These PefCD
homologs are referred to as SatAB in the literature (255). The pef operon consists of a
MarR-like transcriptional regulator (locus tag for strains tested: Spy_0195, gbs1402,
SEQ_0290, SUB_1690, SSUJS14_1996, and DQ08_09375) controlling an adjacent ABCtype

efflux

system

(Spy_0196-97,

gbs1401-00,

SEQ_0292-93,

SUB_1689-88,

SSUJS14_1995-94, and DQ08_09370-65). The neighboring genes upstream and
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downstream from the pef operon consist of lipid metabolism (gpsA) and unknown
functions, respectively. B. The efflux system, PefCD belongs to the class-1 type of ABC
transporters. PefC and PefD both contain a membrane permease domain fused to an
ATPase domain on the same polypeptide chain.
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FIGURE 22.

Figure 22: Insertional inactivation of pefC in GAS leads to impaired growth
phenotype. A. A schematic representation of the pefC::pMZ1 mutation in the ZE4951
strain and the plasmids used for complementation analysis. The aad9 and aphA3 genes
confer the resistance to spectinomycin (SpecR) and kanamycin (KanR), respectively. MCS
is a multiple cloning site. The Ori (pSH71 derivative) enabled replication of plasmids in
multiple hosts (E. coli and GAS). Plasmid pANKITA5b carries the pefRCD cluster
cloned into the MCS in pKSM201. B. Growth of the NZ131 (WT), ZE4951 (Mutant),
ZE4951/pANKITA5b (Complement), and ZE4951/pKSM201 (Empty vector) strains.
Fresh THYB media were inoculated with GAS cells (OD600 nm = 0.05) and the cultures
were grown statically at 37 °C. Cell growth was monitored colorimetrically and
expressed in Klett units. The data are representative of two independent experiments.
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FIGURE 23.

Figure 23: The PefCD transporter protects GAS from heme-mediated lipid
oxidation. A. Lipid peroxidation standard curve. The curve was generated by plotting the
absorbance monitored at 532 nm and formed as a result of reactivity between a series of
malondialdehyde solutions (0, 12.5, 25, 50, and 100 nmol/ml) with the TBA reagent. B.
Lipid peroxidation following heme exposure. Cultures of NZ131 (WT), ZE4951
(Mutant), ZE4951/pANKITA5b (Complement), and ZE4951/pKSM201 (Empty vector)
strains were treated with 1 μM heme during the mid logarithmic phase of growth (60-70
Klett units). Culture samples were then collected at 30, 60, and 90 min post-heme
exposure and allowed to react with TBA. The sample absorption at 532 nm was
determined, and the formation of TBA-reactive-substances (TBARS) was calculated
using the standard curve shown in A. All samples were standardized with respect to cell
number. The data are derived from two independent experiments, each performed in
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triplicates. The asterisk (*) denotes that the observed P value is statistically significant (P
< 0.05) calculated using student t-test (equal variance) at 0.05 levels of significance.
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FIGURE 24.

Figure 24: The PefCD transporter protects GAS chromosome from heme-mediated
GAS damage. A. AP sites standard curve. The curve was generated by plotting
absorbance at 650 nm from a genomic DNA series with 0, 8, 16, 24, 32, and 40 AP sites /
105 bp after reaction with the ARP probe. B. AP site formation in GAS chromosome
following

heme

exposure.

Cultures

of

NZ131

(WT),

ZE4951

(Mutant),

ZE4951/pANKITA5b (Complement), and ZE4951/pKSM201 (Empty vector) strains
were treated with 5 μM heme during the mid logarithmic phase of growth (60-70 Klett
units). Genomic DNA was extracted from samples collected at 0, 30 and 90 min post
exposure was allowed to react with ARP-biotin and analyzed. The sample absorption at
650 nm was determined and AP site formation was calculated using the standard curve
shown in A. All samples were standardized with respect to cell number. The data are
derived from two independent experiments each done in triplicates. The asterisk (*)
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denotes that the observed P value is statistically significant (P < 0.05) and is calculated
using student t-test (equal variance) at 0.05 levels of significance.
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FIGURE 25.

Figure 25: Inactivation of the pefCD transporter leads to cellular accumulation of
heme in cells grown in the presence of heme. A. UV-visible spectra across wavelengths
(250-700 nm) were recorded for organic fractions recovered after acidified chloroform
extraction performed on a range of hemin chloride standards. B. The observed
absorbance at 388, 450, and 330 nms from UV scans (of organic fractions) were plugged
into Ac = 2A388 − (A450 + A330) equation. The Ac values for standards extracted using
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chloroform for a range of hemin concentrations (0-4 μM, with 0.5 μM increments) were
plotted against its hemin concentrations to generate a standard plot. The line equation of a
standard plot was used to extrapolate hemin concentrations in the experimental samples.
Cultures of NZ131 (WT), ZE4951 (Mutant), ZE4951/pANKITA5b (Complement), and
ZE4951/pKSM201 (Empty vector) strains were treated with 3 μM heme during the mid
logarithmic phase of growth (60-70 Klett units). Cells were harvested, washed, and were
subjected to chloroform extraction. C. UV-visible spectra across different wavelengths
(250-700 nm) of the collected organic phases from tests samples were recorded. D. Heme
concentration in the test samples. The concentrations of heme in the test samples were
calculated using the standard curve shown in B. The data are derived from two
independent experiments each performed in triplicates. The asterisk (*) denotes that the
observed P value is statistically significant (P < 0.05) calculated using student t-test
(equal variance) at 0.05 levels of significance.
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FIGURE 26.

Figure 26: A schematic depiction of heme-tolerance transporters described in
streptococci.
Putative homologs of the HrtAB (Class-3 ABC-type transporter) were identified in GBS,
and were shown to be induced by heme. The PefAB and PefCD are heme and PPIX
efflux machineries used by GBS. PefAB is related to the drug/proton antiporter family,
while PefCD consists of Class-1 ABC type transporter. Our data show that GAS employs
PefCD to efflux heme and provide cyto-protective function to various biomolecules.

150

Appendix C: Supplementary Tables
Table 1: The S. pyogenes MGAS5005 Heme stimulon.
Locusa

Geneb

Expressionc

Putative functiond

Activated in the presence of Heme
2.182 ±
Spy0013

ftsH

0.033

Cell division protein - COG0465 [O]
Phosphoribosylaminoimidazole carboxylase

Spy0031

Spy0157

Spy0158

purK

opuAA

opuABC

2.01 ± 0.095

ATPase subunit - COG0026 [F]

2.638 ±

GB transport ATP-binding protein -

0.162

COG4175 [E]

2.127 ±

GB-binding protein/GB transport system

0.147

permease protein - COG2113/4176 [E]

2.552 ±
Spy0186

Spy0195

Spy0196

Spy0197

Spy0275

pefR

pefC

pefD

0.086

Transcriptional regulator - COG1846 [K]

2.778 ±

Transcriptional regulator, MarR family -

0.101*

COG1846 [K]

2.001 ±

MDR ABC transporter ATP-binding and

0.104

permease protein - COG1132 [V]

2.112 ±

MDR ABC transporter ATP-binding and

0.086

permease protein - COG1132 [V]

2.673 ±

Serine/threonine sodium symporter -

0.112

COG3633 [E]
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3.594 ±
Spy0300

0.091

Hydrolase, HAD superfamily - COG1418 [R]

Spy0301

4.24 ± 0.103

Integral membrane protein - COG0670 [R]

2.191 ±

ATP-dependent Clp protease proteolytic

0.061

subunit - COG0740 [O]

Spy0328

clpP

2.036 ±
Spy0329

Spy0382

msrA.2

0.127

Hypothetical cytosolic protein

2.202 ±

Peptide methionine sulfoxide reductase -

0.108

COG0225 [O]

2.539 ±
Spy0383

Spy0385

0.109

D-alanyl-D-alanine carboxypeptidase

2.609 ±

67 kDa Myosin-crossreactive antigen -

0.088

COG0493 [E]

2.162 ±
Spy0423

pepQ

Spy0425

Spy0456

Spy0457

Spy0474
Spy0477

licT

0.074

Xaa-Pro dipeptidase - COG0006 [E]

2.235 ± 0.07

Glycosyltransferase - COG0438 [M]

2.519 ±

Plasmid stabilization system antitoxin protein

0.122

- COG3077 [L]

2.185 ±

Plasmid stabilization system protein -

0.101

COG2026 [J/D]

2.406 ±

Transcription antiterminator, BglG family -

0.099

COG3711 [K]

2.195 ±

Hypothetical membrane spanning protein -
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Spy0479

Spy0483

0.061

COG3689 [S]

2.804 ±

Hypothetical membrane spanning protein -

0.078

COG0785 [O]

4.014 ±

Stress-responsive transcriptional regulator -

0.105

COG1983 [K/T]

3.168 ±
Spy0509

tpi

Spy0534

0.075

Triosephosphate isomerase - COG0149 [G]

2.219 ±

(R,R)-butanediol dehydrogenase/acetoin

0.102

dehydrogenase - COG1028 [I/Q/R]

3.791 ±
Spy0660

fruR

0.165

Fructose repressor - COG1349 [K/G]

4.285 ±
Spy0661

Spy0662

fruB

fruA

0.163

1-phosphofructokinase - COG1105 [G]

2.774 ±

PTS system, fructose-specific IIABC

0.153

component - COG1299/1445/1762 [G/T]

2.111 ±
Spy0677

Spy0694

Spy0743

fms

clpL

0.073

Peptide deformylase - COG0242 [J]

3.928 ±

Putative ATP-dependent Clp proteinase

0.141

(ATP-binding subunit) - COG0542 [O]

3.181 ±

ABC transporter substrate-binding protein -

0.139

COG2984 [R]

2.488 ±
Spy0744

0.113

Hypothetical protein
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Spy0745

2.051 ±

ABC transporter permease protein -

0.147

COG4120 [R]

2.511 ±
Spy0877

0.082

Hypothetical protein

2.527 ±
Spy0878

0.104

Hypothetical protein

2.092 ±
Spy0880

Spy0910

hlyIII

citC

0.123

Putative hemolysin III - COG1272 [R]

2.009 ±

(Citrate [pro-3S]-lyase)-ligase - COG3053

0.058

[C]

2.105 ±
Spy0924

0.131

Transcriptional regulator, GntR family

2.353 ±
Spy0947

ciaH

0.055

TCS histidine kinase - COG1167 [K/E]

2.094 ±
Spy0948

ciaR

0.057

TCS response regulator - COG074 [T/K]

2.188 ±
Spy0982

0.089

Histidine-binding protein - COG0834 [E/T]
Putative competence protein/transcription

Spy1137

coiA

2.296 ± 0.12

factor
Ribosomal small subunit pseudouridine

Spy1138

rsuA

2.823 ±0.136

synthase A - COG1187 [J]

Spy1139

nagB

3.114 ±

Glucosamine-6-phosphate isomerase -
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0.132

COG0363 [G]

2.074 ±
Spy1203
Spy1222

Spy1240

Spy1345

Spy1406

int.2

clpE

atoD.1

copY

0.027

Phage protein

1.94 ± 0.143

Phi5005.2 integrase - COG0582 [L]

5.047 ±

ATP-dependent clp protease ATP-binding

0.174

subunit - COG0542 [O]

2.115 ±

Acetate CoA-transferase alpha subunit -

0.122

COG1788 [I]

2.109 ±

CopAB ATPases metal-fist type repressor -

0.102

COG3682 [K]
Guanine-hypoxanthine permease - COG2252

Spy1477

2.34 ± 0.117

[R]

3.327 ±
Spy1497

dnaJ

0.103

Chaperone protein - COG0484 [O]

Spy1498

dnaK

4.58 ± 0.09

Chaperone protein - COG0443 [O]

3.876 ±
Spy1499

Spy1500

grpE

hrcA

0.112

Hypothetical protein - COG0576 [O]

4.081 ±

Heat-inducible transcription repressor -

0.142

COG1420 [K]

2.491 ±
Spy1559

Spy1633

trx

lacE

0.125

Thioredoxin - COG0526 [O/C]

2.127 ±

PTS system, lactose-specific IIBC component

0.066

- COG1455 [G]
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1.991 ±
Spy1669

def

0.091

Peptide deformylase - COG0242 [J]

2.936 ±
Spy1670

0.101

Oxidoreductase - COG0431 [R]

Spy1709

2.961 ± 0.17

Hypothetical protein - COG3237 [S]

2.448 ±

Hypothetical protein (Mga-associated) -

0.082

COG0477 [G/E/P/R ]

2.585 ±

Immunogenic secreted protein - COG0810

0.131

[M]

Spy1722

Spy1723

isp

2.554 ±
Spy1724

ihk

0.136

TCS histidine kinase - COG0642 [T]

2.719 ±
Spy1725

irr

Spy1727

Spy1728

0.164

TCS response regulator - COG0745 [T/K]

3.699 ±

ABC transporter ATP-binding protein -

0.118

COG1136 [V]

2.458 ±

Periplasmic component of efflux system -

0.127

COG0845 [M]

3.357 ±
Spy1729

0.148

Hypothetical protein

2.691 ±
Spy1730

0.078

Hypothetical protein
Protein export protein PrsA precursor -

Spy1732

prsA

8.63 ± 0.043

COG0760 [O]

156

Spy1753

pbp2A

2.173 ±

Multimodular transpeptidase-transglycosylase

0.036

- COG074 [M]

8.351 ±
Spy1761

groEL

0.134

60 kDa chaperonin - COG0459 [O]

7.951 ±
Spy1762

Spy1763

groES

clpC

0.134

10 kDa chaperonin - COG0234 [O]

2.576 ±

Negative regulator of genetic competence -

0.075

COG0542 [O]

2.567 ±
Spy1764

Spy1798

ctsR

spxA2

0.124

Transcriptional regulator

5.238 ±

suppressor of clpP & clpX, spxA2 allele -

0.093

COG1393 [P]

2.204 ±

UTP--glucose-1-phosphate uridylyltransferase

Spy1853

hasC

0.078

- COG1210 [M]

Spy1865

htrA

3.539 ± 0.12

Protease Do - COG0265 [O]

Repressed in the presence of Heme
Spy0015

0.43 ± 0.158

Hypothetical protein

0.368 ±
Spy0040

Spy0117

adhA

0.112

Alcohol dehydrogenase - COG1064 [R]

0.333 ±

Transcriptional regulator, LysR family -

0.088

COG0583 [K]
Transcriptional regulator, LysR family -

Spy0118

0.374 ± 0.09

COG0583 [K]
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Spy0127

Spy0129

Spy0130

Spy0131

ntpK

ntpC

ntpF

ntpA

0.246 ±

V-type sodium ATP synthase subunit K -

0.275

COG0636 [C]

0.219 ±

V-type ATP synthase subunit C - COG1527

0.274

[C]

0.219 ±

V-type sodium ATP synthase subunit F -

0.258

COG1436 [C]

0.118 ±

V-type sodium ATP synthase subunit A -

0.306

COG1155 [C]
V-type sodium ATP synthase subunit B -

Spy0132

Spy0133

ntpB

ntpD

0.092 ± 0.35

COG1156 [C]

0.138 ±

V-type sodium ATP synthase subunit D -

0.328

COG1394 [C]

0.249 ±
Spy0340

lctO

Spy0361
Spy0562

Spy0563

sagA

sagB

0.124

L-lactate oxidase - COG1304 [C]

0.458 ±

Phosphoglycerate transporter protein -

0.107

COG2271 [G]

0.31 ± 0.19

Streptolysin S biosynthesis protein

0.325 ±

Streptolysin S biosynthesis protein -

0.124

COG0778 [C]

0.334 ±
Spy0564

sagC

0.116

Streptolysin S biosynthesis protein

0.286 ±
Spy0565

sagD

0.129

Streptolysin S biosynthesis protein
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Spy0566

Spy0567

Spy0568

Spy0569

Spy0570

sagE

sagF

sagG

sagH

sagI

Spy0571

Spy0780

Spy0781

Spy0782

Spy0783

ptsA

ptsB

ptsC

ptsD

0.329 ±

Streptolysin S putative self-immunity protein

0.105

- COG1266 [R]

0.273 ±

Streptolysin S biosynthesis protein -

0.135

COG0477 [G/E/P/R]

0.282 ±

Streptolysin S export ATP-binding protein -

0.127

COG1131 [V]

0.304 ±

Streptolysin S export transmembrane protein -

0.146

COG0842 [V]

0.354 ±

Streptolysin S export transmembrane protein -

0.113

COG0842 [V]

0.312 ±

Endonuclease/exonuclease/phosphatase

0.086

family protein - COG2374 [R]

0.069 ±

PTS system, mannose/fructose family IIA

0.312

component - COG2893 [G]

0.073 ±

PTS system, mannose/fructose family IIB

0.298

component - COG3444 [G]

0.093 ±

PTS system, mannose/fructose family IIC

0.262

component - COG3715 [G]

0.369 ±

PTS system, mannose/fructose family IID

0.202

component - COG3716 [G]

0.467 ±
Spy0784

spt5S

0.112

TCS histidine kinase - COG2972 [T]

Spy0830

dpiA

0.419 ±

Transcriptional regulatory protein - COG4565
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0.129

[K/T]

0.273 ±
Spy0901

Spy0905

Spy0906

citD

citE

0.174

Hypothetical protein

0.306 ±

Citrate lyase acyl carrier protein - COG3052

0.183

[C]

0.291 ±

Citrate lyase beta chain/citryl-CoA lyase

0.169

subunit - COG2301 [G]
Citrate lyase alpha chain/citrate CoA-

Spy0907

Spy0908

citF

citX

0.33 ± 0.129

transferase - COG3051 [C]

0.315 ±

Apo-citrate lyase phosphoribosyl-dephospho-

0.107

CoA transferase - COG3697 [H/I]

0.479 ±
Spy0929

Spy0930

0.089

SIR2 family protein - COG0846 [K/E]

0.428 ±

ATPase associated with chromosome

0.103

architecture/replication - COG2110 [R]
Glycine cleavage system H protein -

Spy0931

Spy0932

Spy0933

0.411 ± 0.1

COG0509 [E]

0.416 ±

Luciferase-like monooxygenase - COG2141

0.102

[C]

0.428 ±

Probable NADH-dependent flavin

0.085

oxidoreductase - COG1902 [C]
Nucleoside transport system permease protein

Spy0940

0.48 ± 0.059

- COG4603 [R]
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Spy0941

0.417 ±

Nucleoside transport ATP-binding protein -

0.067

COG3845 [R]

0.459 ±
Spy0942

Spy0944

Spy0951

Spy1058

pstB

malE

0.079

Nucleoside-binding protein - COG1744 [R]

0.443 ±

16S rRNA m(2)G 1207 methyltransferase -

0.074

COG2813 [J]

0.491 ±

Phosphate transport ATP-binding protein -

0.046

COG1117 [P]

0.373 ±

Maltose/maltodextrin-binding protein -

0.135

COG2182 [G]

0.422 ±
Spy1076

glnH

0.047

Transporter - COG0765 [E/T ]

0.468 ±
Spy1084

0.118

Outer surface protein - COG3589 [S]

Spy1161

0.346 ± 0.12

Formate transporter - COG2116 [P]

0.283 ±
Spy1270

arcC

0.152

Carbamate kinase - COG0549 [E]

0.278 ±
Spy1271

0.104

Xaa-His dipeptidase - COG0624 [E]

0.315 ±
Spy1272

Spy1273

arcB

0.125

Arginine/ornithine antiporter - COG1288 [S]

0.402 ±

Ornithine carbamoyltransferase - COG0078

0.091

[E]
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0.483 ±
Spy1286

0.056

DNA polymerase - COG1518 [L]

0.461 ±
Spy1303

aroE

0.149

Shikimate 5-dehydrogenase - COG0169 [E]

0.306 ±
Spy1304

lacZ

0.174

Beta-galactosidase - COG3250 [G]

0.243 ±
Spy1305

trxR

0.158

TCS response regulator - COG4753 [T]

0.345 ±
Spy1306
Spy1307

trxS

0.162

TCS histidine kinase - COG2972 [T]

0.22 ± 0.145

Hypothetical membrane spanning protein

0.168 ±
Spy1308

0.201*

Sugar-binding protein - COG1653 [G]
Sugar transport system permease protein -

Spy1309

Spy1310

Spy1315

0.137 ± 0.18

COG0395 [G]

0.184 ±

Sugar transport system permease protein -

0.146

COG4209 [G]

0.454 ±

Transcriptional regulator, GntR family -

0.053

COG1609 [K]

0.459 ±
Spy1316

0.082

Hypothetical protein - COG3538 [S]

0.234 ±
Spy1376

0.182

Transaldolase - COG0176 [G]

162

0.239 ±
Spy1377

0.136

trans-acting positive regulator

0.322 ±
Spy1378

Spy1379

Spy1380

glpF

glpO

0.099

NADH peroxidase - COG0446 [R]

0.209 ±

Glycerol uptake facilitator protein - COG0580

0.184

[G]

0.181 ±

Alpha-glycerophosphate oxidase - COG0578

0.133

[C]

0.085 ±
Spy1381

glpK

0.255

Glycerol kinase - COG0554 [C]

Spy1539

scrK

0.32 ± 0.088

Fructokinase - COG1940 [K]

0.176 ±

Endo-beta-N-acetylglucosaminidase F2

0.105

precursor

Spy1540

endoS

0.409 ±
Spy1596

Spy1597

Spy1682

glnA

glnR

msmK

Spy1758

0.112

Glutamine synthetase - COG0174 [E]

0.389 ±

Transcriptional regulator, MerR family -

0.078

COG0789 [K]

0.392 ±

Multiple sugar transport ATP-binding protein

0.131

- COG3839 [G]

0.5 ± 0.099

Probable dipeptidase B - COG4690 [E]

0.242 ±
Spy1771
Spy1772

hutU

0.146

Urocanate hydratase - COG2987 [E]

0.22 ± 0.192

Glutamate formiminotransferase - COG3643
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[E]
Formiminotetrahydrofolate cyclodeaminase Spy1773

Spy1774
Spy1775

fhs.2

0.16 ± 0.178

COG3404 [E]

0.136 ±

Formate--tetrahydrofolate ligase - COG2759

0.138

[F]

0.15 ± 0.16

Hypothetical cytosolic protein - COG3758 [S]

0.154 ±
Spy1776

0.182

a

Spy numbers from MGAS5005 genome.

b

When available, gene name is provided.

c

Amino acid permease - COG0531 [E]

Array mean ± standard error. Numbers with an asterisk represent the average of array

means obtained from 2 or more distinct probes for the same locus.
d

Putative function using nomenclature from the J. Craig Venter Institute (JCVI) CMR

database. ABC, ATP-binding cassette; CoA, coenzyme A; GB, Glycine betaine; MDR,
multiple drug resistance; PTS, PEP-dependant phosphotransferase system; TCS, twocomponent system. Further information relative to the gene-encoded protein is provided
using the NCBI Clusters of Orthologous Groups (COG) database. Function categories are
given using the letter-based nomenclature from the COG database. Information storage
and processing: J, translation, ribosomal struture and biogenesis; A, RNA processing and
modification; K, transcription; L, replication, recombinaison and repair; B, chromatin
structure and dynamics. Cellular processes and signaling: D, cell cycle control, cell
division, chromosome partitioning; Y, nuclear structure; V, defense mechanisms; T,
signal transduction mechanisms; M, cell wall/membrane/envelope biogenesis; N, cell
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motility; Z, cytoskeleton; W, extracellular structures; U, intracellular trafficking,
secretion, and vesicular transport; O, posttranslational modification, protein turnover,
chaperones. Metabolism: C, energy production and conversion; G, carbohydrate transport
and metabolism; E, amino acid transport and metabolism; F, nucleotide transport and
metabolism; H, coenzyme transport and metabolism; I, lipid transport and metabolism; P,
inorganic ion transport and metabolism; Q, secondary metabolites biosynthesis, transport
and catabolism. Poorly characterized: R, general function prediction only; S, unknown
function.
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Appendix D: Supplementary Figures

Figure 1: Microarray data validation.

A. A set of 11 genes representing the range of possible changes, i.e. increase (prsA, clpL,
opuAA), decrease (endoS, ptsA, sagA, spt7R) and no effect (slo, fasC, mtsA) were selected
and their expression analyzed by real-time RT-PCR. B. Plotting the log value of the array
on the x-axis against the log value of the real-time RT-PCR on the y-axis revealed strong
correlation (calculated R2 = 0.892) between the two datasets.
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